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Abstract 
An investigation of the substrate requirements of the interleukin-113 (IL-113) 
converting enzyme (ICE) has been carried out. Solid phase peptide synthesis has been 
used to synthesise sequences from precursor IL-i 13,  a cowpox inhibitor crmA, and the 
pro region of ICE. The peptides have been assayed to ascertain their inhibitory 
properties. 
In the course of this work an attempt has been made to establish a simple way of 
introducing 13-turns into peptides. This has been carried out by the formation of a 
disulphide bridged species in which cystine formation was facilitated by the use of the 
turn-inducing 'ProD.Val' moiety, and by the introduction of an unnatural amino acid, 
cis-3-aminocyclopentane- 1 -carboxylic acid (ACPC). 
The 13-turns developed in the ICE work have been introduced into a peptide 
containing a discontinuous epitope of gpl2O, and have been found, in this instance, to 
be interchangeable with one another, and with the 'y-turn Cys-Val-Cys. 
Abbreviations 
AAA amino acid analysis 
ACPC cis-3-aminocyclopentane- 1 -carboxylic acid 
AE activated ester 
AMC 7-amino-4-methylcoumarin 
Boc i-butyloxycarbonyl 
CD circular dicbroism 
cDNA complementary deoxyribonucleic acid 
CHAPS 3- [(3 -cholamidopropyl)dimethylammonio] -1 -propanesulphonate 
crmA cytokine response modifier A 
DCC N,N' -dicyclohexylcarbodiimide 
DCM dichioromethane 





DQ COSY double quantum filtered correlation spectroscopy 
DTNB 5,5 '-dithiobis(2-nitrobenzoic acid) 
DTT dithiothreitol 
EDT ethanedithiol 
EDTA ethylenediaminetetracetic acid 
El electron ionization 
FAB fast atom bombardment 
Fmoc 9-fluorenylmethyloxycarbonyl 
HCMV human cytomegalovirus 
HEPES N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid] 
HOAt 1 -hydroxy-7-azabenzotriazole 
HOBt 1 -hydroxybenzotriazole 
HOCt ethyl-i -hydroxy- in-i ,2,3 -triazole-4-carboxylate 
HPLC high performance liquid chromatography 
ICE interleukin-1 13  converting enzyme 
Ig immunoglobulin 
IL interleukin 
IL-1R interleukin- 1 receptor 
IL-ira interleukin-1 receptor antagonist 
mRNA messenger ribonucleic acid 
NOESY nuclear Overhauser effect spectroscopy 
NTB nitrothiobenzoate 
PGC porous graphitised carbon 
p rolL-i 13 precursor interleukin- 113 
RA rheumatoid arthritis 
RSL reactive site loop 
Rt retention time 
SA symmetrical anhydride 
SPPS solid phase peptide synthesis 
TOCSY total correlation spectroscopy 
TOF time of flight 
TbFmoc 1 7-tetrabenzo [a, c, g, i]fluorenylmethoxycarbonyl 




TMSBr trimethylsilyl bromide 
TNF tumour necrosis factor 
The Naturally Occurring Amino Acids 
-their 3 & 1 letter codes 
Amino Acid 3 letter code 1 letter code 
Alanine Ala A 
Arganine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamic Acid Glu E 
Glutamine Gin Q 
Glycine Gly G 
Histidine His H 
Isoleucine lie I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
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1. Introduction 
1.1 Interleukin-113 
The interleukins are a subset of the cytokines, protein hormones which mediate and 
regulate the immune and inflammatory responses. The cytokines are a diverse group 
which nonetheless share a number of characteristics. The same biological effects can 
often be attributed to several cytokines, despite the fact that they bind to different 
receptors, and additive or synergistic effects are often seen when two or more 
cytokines are present. For example, despite having distinct receptors, interleukin- 1 
(IL-1) and tumour necrosis factor (TNF) have remarkably similar biological 
properties, and when used together in experimental studies the observed effect often 
exceeds the additive effect of the individual hormones working alone'. Cytokines 
often regulate the production of other cytokines and cytokine receptors: for example, 
IL-1 production is up-regulated both by itself and by transforming growth factor 
(TGF)132, but down-regulates its own receptor'. 
1.1.1 Biological Effects of IL-1 
The term IL-i encompasses two distinct gene products, IL-la and IL-113. Despite 
showing only 26% sequence homology in humans,4 they bind to the same receptors 
and share many biological properties'. 
IL-1 has both systemic effects, being fever- and sleep-inducing, and causing appetite 
suppression, and local autocrine/paracrine effects. Its immunostimulatory properties 
include the augmentation of T, B and natural killer cell responses. IL-i is also 
proinflammatory. It induces endothelial cells to release the prostagiandins PGI2 and 
PGE2, and to increase their expression of the intercellular adhesion molecule 
(ICAM)-1, which causes adhesion of neutrophils, monocytes and lymphocytes. IL-I 
is, in addition, chemotactic for monocytes, lymphocytes and neutrophils so that 
cellular infiltration occurs at the site of IL-1 release. This, taken with the fact that 
IL-i initiates blood clotting, thus decreasing blood flow, acts to localise tissue 
inflammation. 
IL-1 has both catabolic and anabolic effects. It induces collagenase production and 
release of metalloproteinases and proteoglycariases, all of which mediate the 
destruction of bone and cartilage. However, it also causes angiogenesis, the 
migration and proliferation of endothelial cells which results in the formation of new 
blood vessels, and collagen synthesis. 
1.1.2 Rheumatoid Arthritis 
Around 2% of the world's population suffer from rheumatoid arthritis (RA), with 
three female sufferers for every male. Whilst RA is associated with systemic effects 
such as fever and muscle wasting, it is primarily a disease of the synovial joints (Fig. 
1.1). In an RA patient these joints are swollen and painful, and destruction of 





ntains synovial fluid) 
Fig. 1.1. A synovial joint 
The pathology of RA suggests that IL-1 may be an important mediator of the 
diseases, and the presence of IL-1 in the synovial fluid of rheumatoid joints is well 
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established. It has been shown that mononuclear cells from RA patients release IL- 
1 t3  far more rapidly in response to antigenic challenge than do cells from healthy 
controls. Administration of murine recombinant IL-1 to mice during the chronic 
phase of antigen-induced arthritis results in a flare-up of the smouldering 
inflammation in the joints that is analogous with the flare-ups seen in human RA6, 
and blocking the action of IL-1 reduces bacterial-cell-wall-induced arthritis in ratss. 
Many of the symptoms of RA could be directly or indirectly related to the presence 
of IL-1. The rheumatoid synovial lining is characterised by its heavy infiltration by 
inflammatory cells such as lymphocytes and macrophages (IL-1 is chemotactic for 
such cells) and the growth of new blood vessels (angiogenesis is stimulated by IL-
1). The pain associated with rheumatoid joints is thought to be due to the PGE2 
found in the synovial fluid; as previously noted, ILA induces prostaglandin 
production in endothelial cells. It has been shown that IL-1 stimulates osteoclast 
recruitment by a mechanism involving prostaglandins, probably PGE2 . Osteoclasts 
break down the calcified intercellular structure of bone. In addition, IL-i regulates 
the production of matrix metal loproteinases such as collagenase and stromelysin'°, 
which in turn regulate the breakdown of cartilage. It is interesting to note that IL-i 
has been implicated in post-menopausal bone loss leading to osteoporosis". 
It has been demonstrated that the predominant source of IL-fl3 in the synovial tissue 
of RA patients is CD14 positive macrophages 12.  Whilst not all the CD14 positive 
macrophages present secrete IL-113, those doing so are generally found in pairs or 
clusters, a finding consistent with the fact that IL-1 induces production of further 
IL-i. 
It should be emphasised that, whilst IL-i may play a key role in the progression of 
RA, it is not the initial cause. IL-1 is produced in response to disease, and 
3 
subsequently acts as a mediator of tissue destruction. The body produces natural 
inhibitors of IL-i activity which may be co-induced with IL-1 itself. It seems likely 
that, in autoimmune diseases such as RA, there is an imbalance between IL-i and its 
inhibitors, so that IL-1 is not down-regulated effectively and an abnormal 
inflammatory response develops". 
1.1.3 IL-1: Two Gene Products - a and 13 
IL-i a and 13 are both produced as 31 kDa propeptides which can undergo proteolytic 
processing to mature 1 7kDa products. Despite having relatively low sequence 
homology (26%), the mature forms adopt the same tertiary structure, a structure 
which is shared with soybean trypsin inhibitor and fibroblast growth factor (FGF); it 
has been dubbed the 'IL-i fold". The gross structure is that of a barrel, open at one 
end. The barrel is constructed from twelve anti-parallel 13-strands, three pairs 
forming the 'struts' and the remaining three covering the 'closed' end. The structure 
has three-fold rotational symmetry; it consisits of three subunits, each taking the 
form of three 13-strands, a loop and a final 13strand15 (Fig. 1.2). The inner core of the 
barrel is lined with hydrophobic residues. 
Given their similar structures, it is perhaps not surprising that mature IL-i a and 13 
bind to the same receptors with similar affinities. However, whilst prolL-la also 
binds to the receptor and elicits a biological response, prolL-1 13 does not bind16. This 
suggests a difference in the structures of the a— and 13-forms such that the cleaved 
portion of prolL-i 13 sterically inhibits interaction with the receptor, whilst that of 
prolL-ia does not. Inspection of the crystal structures of mature IL-la and 13 shows 
that, whilst in both cases the N and C termini are situated at the open end of the 
barrel, in IL-la they are at opposite sides of the 'rim' whereas in IL-113 they are close 
together' 1,17. 
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Fig. 1.2. The structure of IL-113 
a. Schematic of IL-13 showing the pseudo-3-fold symmetry 
b. Ribbon diagram of IL-1P, viewed from the open end of the barrel 
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Since the biological activities of IL-la and 13 are so similar, the reason for the 
maintenance of two separate gene products is uncertain. However, insight may be 
gleaned from differences in the kinetics of secretion of the two forms. IL-i 13 has a 
much shorter intracellular half life than IL-la (2.5 hours compared with 15 hours), 
and in addition is released much sooner after stimulation of the cell18.  In general, IL-
I x tends to remain associated with the cell, with IL-I 13  being the main secreted form. 
IL-i activity is expressed on the cell surfaces of macrophages and is associated with 
a protein of approximately 30kDa molecular weight, suggesting a membrane-bound 
form of prolL-ia. It has been shown that transfection of fibroblasts with prolL-la 
cDNA results in the expression of membrane-associated IL-i activity, whereas 
transfection with prolL-113 cDNA does not9. It has been suggested that this 
membrane-bound prolL- 1 a could interact with T cell IL-1 receptors during antigen 
presentation by the macrophage thus up-regulating the T cell response (Fig. 1.3). 
Therefore it appears that the cell-associated IL-la may play a larger part in 
immunostimulation, whilst the freely moving, extracellular IL-l13 may be more 
important in regulating the inflammatory response. 
IL-la IL-113 
Propeptide 31 kDa Propeptide 31 kDa 
Mature form 1 7kDa Mature form 1 7kDa 
Adopts the 'IL-i fold' Adopts the 'IL-i fold' 
Binds to type I and type II Binds to type I and type II 
receptors receptors 
Precursor is biologically active Precursor is not biologically 
active 
Mainly cell-associated Mainly extracellular 
Immunostimulatory Proinflammatory 






antigen presenting 	foreign 











Fig. 1.3. Cartoon showing the proposed interaction of cell surface IL-1 with the 
T cell receptor, resulting in up-regulation of the immune response 
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1.1.4 The IL-1 Receptor and its Interaction with IL-113 
Two IL-1 receptors have been described, designated type I and type II. Although 
their extracellular structures are very similar, the type II receptor has a very short 
cytoplasmic domain of only 29 amino acids. This has led to doubts as to whether IL-
1R II is a true receptor, capable of transmitting signals across the cell membrane. 
Whilst a chimeric receptor composed of the extracellular and transmembrane regions 
of type II and the cytoplasmic domain of type I has been shown to mediate IL-1 
effects20, there is evidence that the type II receptor itself does not transduce signals. 
It has been suggested by Colotta et a121 that the type II 'receptor' is, rather, a decoy 
trap for IL-1, thus assisting in the regulation of this cytokine. 
The type I receptor is found predominantly on T cells, fibroblasts and macrophages. 
However, since very low levels of receptor occupancy are required for signalling to 
take place, it is possible that other cell types that respond to IL-i carry IL-1R I in 
undetectably small amounts. It is interesting that, whilst low levels of IL-i result in a 
biological response, at higher IL-i levels the IL- 1 R/cytokine complex is observed to 
undergo endocytosis. Internalised IL-1 is thought to become associated with the 
nucleus, and it is possible that interaction of IL-1 with nuclear receptors may be 
important for some of its biological effects22. 
The type I receptor consists of three distinct regions23. The transmembrane region is 
a single strand, 21 amino acids long, composed predominantly of hydrophobic 
residues. The extracellular region is 319 amino acids long and is organised into three 
immunoglobulin(Ig)-like domains. Such domains consist of a pair of n-strands, 
pinned together by a disulphide bond. The cysteines and certain other key residues 
important for structure formation are highly conserved in all Ig-like molecules, but 
typically minimal amino acid similarity is seen at other positions. This structural 
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organisation (shared with IL-1R II) makes the IL-1R a member of the 
immunoglobulin superfamily. The platelet-derived growth factor (PDGF) receptor is 
also a member of this class. The extracellular region contains seven potential N-
linked glycosylation sites, and the IL-1R I is known to be glycosylated on Asn. The 
cytoplasmic domain is 217 amino acids long and shows no significant similarity to 
known sequences. In particular, it has no regions typical of tyrosine kinases as found 
in other Ig-like receptors. The signalling mechanism is thus unclear, but may involve 
a novel, as yet uncharacterised, protein kinase24. 
Various studies have attempted, by the use of site-directed mutagenesis and 
neutralising antibodies, to define the regions of IL-i J3 that are important for IL-i R I 
binding. Residues that have been identified as important are Arg-120, Leu-122, Phe-
162, Ile-172, Lys-208, Lys-209, Lys-210, Arg-214, Lys-219 and Glu-221725. All 
these residues are situated on the rim of the open end of the 'IL-i fold barrel'. Further 
residues have been identified which, whilst apparently having a minimal effect on the 
binding energy, are important for biological activity. Analysis of such results has led 
Clore et a126  to propose three distinct regions of IL-i l, each of which interacts with 
one of the Ig-like domains of the IL-1R. The first region, defined by the residues 
specified above, is thought to contribute most to the binding energy, with the 
remaining two sites playing a part in signal transduction. 
1.1.5 Blocking IL-1 
1.1.5.1 IL-1 Binding Proteins 
There are conceivably two ways in which proteins and peptides can prevent 
interaction of IL-1 with its receptor and hence modulate its biological effects; they 
may interact either with IL-i itself or with the receptor. Various proteins of the first 
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type are known. The first of these, uromodulin, is an 85kDa glycoprotein found in 
the urine of pregnant women and produced in the kidneys. Its activity depends on 
correct glycosylation and it binds both IL-1 and TNF. Its role appears to be the 
removal of IL-1 from the blood stream2728. 
Symons et a129 have described an IL-1 binding protein found in the supernatant of 
stimulated Raji B cells. They suggest that this is a proteolytically cleaved form of 
the IL-1R. Interestingly, this soluble IL-1R binds both precursor and mature IL-I13, 
but not IL-la. A similar IL-113-specific binding protein has been found to be 
secreted by vaccinia and cowpox viruses. The 33kDa B15R gene product is a 
member of the immunoglobulin superfamily and shows significant homology to the 
IL-i R II. The B 1 5R gene is thought to be under the control of an early promoter, 
meaning that expression may be rapid and abundant after infection. Thus such gene 
products help to knock out the host defence mechanisms, giving the virus an 
advantage in the early stages of infection 30,31. 
It has been reported that a synthetic peptide, amino acids 86-93 of the extraceilular 
domain of the human IL-1R I, binds to both IL-la and 13, preventing their interaction 
with the receptor and hence inhibiting biological activity". 
1.1.5.2 The IL-1 Receptor Antagonist 
The second type of IL-1 inhibitor, those that interact with the receptor, is represented 
by the third member of the IL-1 gene family, the IL-1 receptor antagonist (IL-Ira). 
IL-ira was purified from human monocytes by Hannum et a132.  It was obtained as 
three glycosylation variants of a single protein, of nonglycosylated weight 1 8kDa; 
the glycosylated and nonglycosylated forms have the same inhibitory activity. The 
protein has been shown to be a true antagonist, binding to the receptor but eliciting 
10 
no response; the IL-lraIIL-1R complex is not internalised. IL-ira has been shown 
to block the activity of IL-i in vitro and in vivo, and to reduce the severity of disease 
in various animal models, notably to reduce joint swelling by 60% in a rat model of 
J?8 
Comparison of the amino acid sequences of IL-ira, IL-la and IL-ip reveals 18% 
homology between IL-ira and IL-la and homology of 26% between IL-ira and IL-
lf3. Therefore it is unsurprising that IL-Ira appears to adopt the 'IL-1 foid'36. 
However, unlike IL-i a and 13 which are secreted from the cell by an uncharacterised 
pathway, IL-ira has a classical leader sequence and secretion occurs in the 
conventional way. Hence IL-ira exists as glycosylated species, whereas neither IL-
lot nor 13 is seen in glycosylated forms, despite the existence of potential 
glycosylation sites. Virtually all the IL-ira produced by a cell is exported, whereas 
significant amounts of IL- ia and 13  remain cell-associated. 
It has been suggested that the severity of certain disease states may be due to an 
imbalance in the production of IL-ira and IL-lp/cc. The anti-inflammatory cytokine 
interleukin-4 (IL-4) up-regulates the production of IL-ira in stimulated monocytes, 
but down-regulates IL-i a and P. In an animal model of arthritis, treatment with IL-4 
has been shown to increase expression of IL-ira with an accompanying suppression 
of joint swelling and tissue destruction°. 
Human cytomegalovirus (HCMV), an important cause of morbidity in 
immunosuppressed individuals, alters immune function. Monocytes infected with 
HCMV show altered cell-mediated immune responses. It has been shown that 
HCMV immediate early (IE) gene products regulate both IL- 113 and IL- ira mRNA, 
together causing increased release of IL-ira. Of the two IE gene products, 1 and 2, 
1E2 up-regulates IL-ira mRNA expression and protein release, and IE1 down- 
regulates it, whilst these genes have the directly opposite effect on IL-i P. Hence 
immune function can be increased or decreased depending on which gene product 
predominates in the cell4l. 
Due to the extremely low occupancy (2-15%) of the IL-1R required for a biological 
response, large molar excesses (100-300 fold) of IL-Ira are generally required to 
inhibit the action of IL-1. Nonetheless, recombinant IL-ira has been used in 
clinical trials for the treatment of rheumatoid arthritis. 
1.1.6 Processing and Secretion - the IL-113 Converting Enzyme 
All forms of IL-1, a and 13, precursor and mature, are found in the culture supernatant 
of monocytes; thus processing of the precursor to the mature form is not necessary 
for secretion". In addition, no mature IL-i is found within the cell, and the precursor 
does not undergo processing after secretion. Therefore processing must occur 
immediately prior to secretion, which occurs via a novel pathway enhanced by an 
elevation in intracellular calcium ions. 
As previously mentioned, whilst IL-la and 13 are very similar structurally and in their 
biological effects, their secretion kinetics are quite different. 	It is perhaps 
unsurprising, therefore, that the two precursors are processed to the mature forms by 
different enzymes, IL-la by calpain, a calcium-dependent protease, and IL-113, 
between Aspl16 and A1a117 (Fig. 1.4), by the IL-ip converting enzyme (ICE). 
Since only the mature form of IL-I13 is capable of effecting a biological response, 
ICE is clearly an important therapeutic target, the more so given the high specificity 
of this enzyme for its substrate. 
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I MAEVPKLASE MMAYYSGNED DLFFEQDGPK QMKCSFQDLD LCPLDGGIQL 
51 RISDHHYSKG FRQAASVVVA MDKLRKNLVP CPQTFQENDL STFFPFIFEE 
101 EPIFFDTWDN EAYVHDAPVR SLNCTLRDSG QKSLVMSGPY ELKALHLQGQ 
151 DMEQQVVFSM SFVQGEESND KIPVALGLKE KNLYLSCVLK DDKPTLQLES 
201 VDPKNYPKKK MEKRFVFNKI EINNKLEFES AQFPNWYIST SQAENMPVFL 
251 GGTKGGQDIT DFTMQFVSS 
Processing 
APVR SLNCTLRDSG QKSLVNSGPY ELKALHLQGQ 
151 DMEQQVVFSM SFVQGEESND KIPVALGLKE KNLYLSCVLK DDKPTLQLES 
201 VDPKNYPKKK MEKRFVFNKI EINNKLEFES AQFPNYIST SQAENT'4PVFL 








Asn Glu Ala Tyr Val His Asp I Ala Pro Val Arg Ser Leu Asn 
P7 p6  P5 P4 P3 P2 P1 	P1 ' P2' P3' P4' P5' P6' P7' 
Fig. 1.4. Sequence and processing site of precursor IL-1 
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Amino Acid Position 	CA cyclohexyl Ala 
dA • DAla 
dO - 0-Aso 
Fig.1.5. Effect of amino acid substitution on ICE activity 
ICE activity of a pentapeptide with the indicated substitutions, relative to AcYVADG 
after Miller et a184 
Several groups have investigated the substrate specificity of ICE434445. The enzyme 
has an absolute requirement for an aspartic acid residue adjacent and N-terminal to 
the scissile bond; no other residue, including glutamic acid, is tolerated at this 
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position. In addition, ICE prefers a small, hydrophobic residue (Gly or Ala) on the 
C-terminal side of the cleavage site. Other positions are more tolerant of amino acid 
substitutions, particularly P2 (Fig. 1.5). Investigation of the minimum recognition 
sequence for the enzyme has shown that only the four residues N-terminal to the 
cleavage site of prolL- 113 are required. This has led to the development of substrates 
such as 1 and 2 which can be used in fluoresence and UV assays respectively. 
Me 
Ac Tyr Vat Ala Asp 	
Ac T Vat Ala Asp 
(1) 	 (2) 
ICE does not cleave prolL- 1 c, and other proteins that contain an Asp-Ala sequence, 
such as transferrin, actin and C9, are unaffected by ICE. In fact the only known 
substrates of ICE are prolL-1 f3 itself and short, synthetic peptides from the cleavage 
site of prolL- 113.  ProlL- 113 is cleaved at two sites, at Asp 11 6-Alal 17 to give mature 
IL-i 13, and between Asp27 and G1y28. 
ICE has been cloned 46,41  and, very recently, its X-ray structure has been elucidated". 
It is co-induced with IL-149, in monocytes and monocyte-like cell lines", as a 45kDa 
proenzyme. The proenzyme (Fig. 1.6) is processed to give two fragments, of 
approximate molecular weights 20kDa and lOkDa and hence designated p20 and 
plO, both of which are required for enzyme activity46. ProICE has four processing 
sites, Aspl03-Serl04, Aspl 19-Asnl2O, Asp297-Ser298 and Asp316-A1a317. The 
fact that all these sites are of the Asp-Xxx type appears to be significant, as there is 
evidence that proICE processing may be autocatalytic46. 
ICE has been shown to be a cysteine protease, and the active site cysteine has been 
identified as Cys285 which is situated in p2046. However, ICE is a novel protease, 
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bearing no resemblance to other, well-known cysteine proteases such as papain and 
cathepsin B. 
1 MADKVLKEKR KLFIRSMGEG TINGLLDELL QTRVLNKEEM EKVKRENATV 
51 MDKTRALIDS VIPKGAQACQ ICITYICEED SYLkGTLGLS ADQTSGNYLN 
101 MQDSQGVLSS FPAPQAVQDN PAIVIPTSSGSE GNVKLCSLEE AQRIWKQKSA 
151 EIYPIMDKSS RTRLALIICN EEFDSIPRRT GAEVDITGMT MLLQNLGYSV 
201 DVKKNLTASD MTTELEAFA}I RPEHKTSDST FLVFMSHGIR EGICGKKHSE 
251 QVPDILQLNA IFNMLNTKNC PSLKDKPKVI IIQACRGDSP GVVWFKDSVG 
301 VSGNLSLPTT EEFEDDAIKK AIIEKDFIAF CSSTPDNVSW RHPTMGSVFI 
351 GRLIEHMQEY ACSCDVEEIF RKVRFSFEQP DGRAQMPTTE RVTLTRCFYL 
401 FPGH 
Fig. 1.6. The 45kDa proenzyme 
p20 and plO underlined 
At first it was supposed that ICE was a heterodimer composed of a plO and a p20 
subunit; however, from the X-ray crystal data of ICE co-crystallised with the 
tetrapeptide aldehyde reversible inhibitor AcTyrValAlaAspH48 and the tetrapeptide 
chioromethylketone irreversible inhibitor AcTyrValAlaAsp-CMK85, it appears that 
the enzyme is a tetramer composed of a pair of heterodimers (Fig. 1.7). The overall 
structure is that of two adjacent p10 subunits enfolded by two p20 subunits. That 
most of the interaction between the heterodimers occurs through p10 is consistent 
with the fact that plO is more highly conserved (81%) between human and murine 
ICE than p20 (59%)51.  Of the sixteen plO and six p20 residues located at the tetramer 
interface, thirteen and four respectively are conserved. It might be supposed that the 
p20 and plO units of a heterodimer would originate from the same proenzyme; 
however, consideration of the p20 C-terminal-plO N-terminal distances leads to the 
conclusion that each heterodimer arises from two 45kDa molecules. 
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Consideration of the proposed active site reveals why both p20 and plO are required 
for enzyme activity, as it spans the subunits. The important catalytic residues, 
Cys285 and His237, are located on p20, whilst plO residues Va1338 and Trp340-
Pro343 form the S2 to S4 interaction sites. Residues from both p20 and plO, Arg179 
Fig. 1.7. The structure of ICE 
Reproduced with permission from Dr K Wilson, Vertex Pharmaceuticals and Nature 
370270 Copyright (1994) Macmillan Magazines Limited 
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and Arg341, are believed to interact with the P1 Asp, with Arg179 being the more 
important residue in this respect. The P2 and P3 residues of the inhibitor used for co-
crystallisation are seen to be exposed to the solvent, explaining the high substitution 
tolerance at these positions. Based on their observations, Wilson et al have proposed 
a mechanism for the action of ICE (Fig. 1.8). 
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Fig. 1.8. Proposed mechanism for ICE 
The cloning of the gene ced-3 from the nematode Caenorhabditis elegans has led to 
the proposal of a second role for ICE, since it shares significant sequence homology 
with the protein CED-352. The proteins share 29% amino acid identity overall, with 
this figure rising to 43% in the most highly conserved regions, 246-360 of CED-3 
and 166-287 of ICE. In particular, the pentapeptide QACRG containing the active 
site Cys is conserved between human and murine ICE and CED-3 of three nematode 
species, suggesting that CED-3 may also function as a cysteine protease. 
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The ced-3 gene is crucial for the induction of programmed cell death (apoptosis), 
which is vital for normal growth and development. Due to its striking sequence 
similarity, it has been suggested that ICE may also act as a cell death protein, and it 
has been shown that overexpression of murine ICE in rat fibroblast cells causes 
apoptosis, a process which can be prevented by co-expression of an inhibitor of 
ICE". These studies raise the interesting possibility that inhibition of ICE may prove 
an effective treatment for many more pathological conditions than was previously 
thought. 
1.1.7 Inhibition of ICE 
1.1.7.1 Synthetic Inhibitors 
All the synthetic inhibitors of ICE known to date are based on the tetrameric peptide 
minimum recognition sequence from proIL-1; no small organic molecules have yet 
been discovered that act as efficient inhibitors. 
Reversible inhibition 
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Fig. 1.9. Reversible and irreversible enzyme inhibition 
Enzyme inhibitors fall into two classes, reversible and irreversible (Fig. 1.9). Peptide 
aldehydes are well known reversible inhibitors of serine and cysteine proteases; they 
mimic the tetrahedral intermediate formed during the enzyme-catalysed hydrolysis 
and are therefore known as transition-state analogues. The tetrapeptide aldehyde 
AcTyrValAlaAspH has been synthesised and found to be an inhibitor of ICE with a 
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K1 of 0.76L0. 1 6nM'4. Whilst peptide aldehydes are often of low utility because of 
their low specificity, being inhibitors of both serine and cysteine proteases, the very 
unusual recognition requirements of ICE may make this a useful inhibitor. 
A second class of reversible ICE inhibitors, the phenylalkyl ketones, have been 
developed by the same group". The strategy was based on evidence for a 
hydrophobic binding pocket in the P1 '-P2' region; various ketones of the general type 
AcTyrValAlaAspR were prepared, where R was a phenylalkyl group and the length 
of the alkyl chain was varied. A dramatic increase in inhibitor potency was seen with 
increasing chain length (Fig. 1.10). 
CO2H 
R1 	R2 	 R3 	K/nM 
H 	H 	PhCH2 	
3 100 
H 	H 	Ph(CH2)2 	
610 
H H Ph(CH2)3 
100 
CH3CONH OH Ph(CH2)4 42 
CH3CONH 	OH 	Ph(CH2)5 	18.5 
Fig. 1.10. Phenylalkyl ketone ICE inhibitors 
Irreversible enzyme inhibitors form a covalently bonded complex with the enzyme 
active site, their activity being described by the rate at which the enzyme is 
inactivated. The irreversible inhibitors of ICE described to date all take the form of a 
peptide methyl ketone, derivatised with a good leaving group: for example the 
fluoromethyl ketones, eg. AcHisAspCH2F and AcTyrAspCH2F56, the diazomethyl 
ketone AcTyrVaIA1aAspCH2N246 (k= 1 .64±0.03x 1 0M' s') and the (acyloxy) methyl 
ketones" (Fig. 1.11). The detailed mechanism for inhibition by such species is not 
known; however, inactivation of cathepsin B via an appropriate (acyloxy) methyl 
ketone proceeds by expulsion of the aryl carboxylate leaving group to give a 
thiomethyl ketone (Fig. 1.12). 
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Fig. 1.11. (Acyloxy) methyl ketone ICE inhibitors 
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Fig. 1.12. Inactivation of a cysteine protease by an (acyloxy) methyl ketone 
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1.1.7.2 Natural Inhibition 
It was noted previously (section 1.1.5.1) that the vaccinia and cowpox viruses encode 
a protein which inhibits the action of IL-i by mimicking a soluble IL-i R. That such 
viruses adopt a multi-pronged approach to attacking the host defence system is 
demonstrated by the discovery that the cowpox virus also encodes a specific inhibitor 
of 10E5859 (Fig. 1.13). 
The inhibitor is encoded by the cytokine response modifier gene, crmA. CrmA is a 
3 8kDa protein which has been classed, from its amino acid sequence similarity, as a 
member of the serpin superfamily. The serpins are serine proteinase inhibitors; 
CrmA is the first cysteine protease inhibitor in the class. 
Most serpins have a molecular weight in the range 45-1OOkDa; thus, at 38kDa, CrmA 
is smaller than other members of the superfamily. However, CrmA shares certain 
stability characteristics with the other inhibitory serpins. Serpins can exist in three 
conformational states, latent, cleaved and inhibitory, with only the latter state being 
active towards their target proteases. Serpins in their inhibitory state are very 
unstable, unfolding in 24M urea. CrmA undergoes such an unfolding transition in 
34M 	However, in both its reactive site loop cleaved form and its complex 
with ICE it is stable to 8M urea, a situation also found for other serpins. Study of the 
kinetics of the ICE/CrmA interaction has found a K1 value of <4x1 0'2M and a half-
life for complex dissociation of >160 minutes at 37°6• 
Alignment of the sequence of CrmA with those of other serpins has led to the 
prediction of a reactive site. Interestingly, the tetrapeptide sequence corresponding to 
P4-P1 of the other serpins, LeuValAlaAsp, is very similar to the sequence contained 
in the optimum substrates, TyrValAlaAsp. 
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MDIFREIASS MKGENVFISP PSISSVLTIL YYGANGSTAE 
41 QLSKYVEKEA DKNKDDISFK SMNKVYGRYS AVFKDSFLRK IGDNFQTVDF 
91 TDCRTVDAIN KCVDIFTEGK INPLLDEPLS PDTCLLAISA VYFKAKWLMP 
141 FEKEFTSDYP FYVSPTEMVD VSMMSMYGEA FNHSVKESF GNFSIIELPY 
191 VGDTSMVVIL PDNIDGLESI EQNLTDTNFK KWCDSMDAMF IDVHIPKFKV 
241 TGSYNLVDAL VKLGLTEVFG STGDYSNMCN SDVSVDAMIH KTYIDVNEEY 
291 TEAAAATCAL VADCASTVTN EFCADHPFIY VIRHVDGKIL FVGRYCSPTT 
TEAAATCALVADCASTVTNEFCAD 
Fig. 1.13. The sequence and proposed reactive site of CrmA 
1.2 Solid Phase Peptide Synthesis 
The synthesis of peptides is a challenge which has occupied chemists throughout the 
20th Century, unsurprising given the role which peptides can play in advancing our 
understanding of many biological processes. Whilst recent years have seen the rise 
of biosynthetic methods of peptide and protein synthesis, the chemist will continue to 
have an important part to play; chemical synthesis allows the introduction of 
unnatural and D-amino acids, and of isotopic labels at specific residues, and 
continuing methodological advances now allow the rapid synthesis of milligram 
quantities of pure peptides of ever increasing molecular weight. 
1.2.1 Strategies for Peptide Synthesis 
The challenge of synthesising even small peptides by conventional chemical 
techniques is far from trivial, amino acids being by nature highly functionalised 
species. Taking as an example the synthesis of a dipeptide, AB, simply reacting the 
22 
two amino acids in the presence of a coupling reagent will result in four possible 
dimers, only one of which is the correct product (Fig. 1.14), with the additional 
possibility of contamination by trimers, tetramers, etc. If the side-chains of amino 
acids A and B are also functionalised, as in, for example, lysine which carries an 
amino group, and aspartic or glutamic acid, carrying carboxylic acid functions, the 
possibility of cross-reactions increases accordingly. Clearly, then, protecting groups 
are required to ensure unambiguous synthesis, and, if the dimer AB is to be extended, 
the N, side chain and carboxyl protecting groups must all be labile under different 
conditions, in addition to being stable to the conditions of the coupling reaction itself 
(Fig. 1.15). 
Larger peptides may be synthesised by one of three strategies: linear, either from N-
to C-terminus (as in nature) or from C- to N-, or convergent (Fig. 1.16). Assuming 
that each of the steps shown in figure 1.16 gives a 90% yield, the overall yield of 
tetramer by the convergent route will be 73%, whereas for each of the linear routes it 
will be 66%. It would therefore appear that convergent synthesis by fragment 
condensation would be the method of choice. However, as will be discussed later, 
there are good chemical reasons for choosing to synthesise peptides linearly from the 
C-terminus (see section 1.2.4). 
At each stage of a solution phase synthesis the product must be purified, by 
recrystallisation, chromatography, etc., a process which is both time-consuming and 
costly in terms of mechanical losses. Thus it is not hard to imagine that the synthesis 
of even a relatively small peptide might take a team of chemists several weeks. The 
potential for peptide synthesis was therefore revolutionised when, in 1959, Bruce 
Merrifield described the concept of solid phase peptide synthesis (SPPS). 
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Fig. 1.14. Undirected coupling of amino acids A and B 









Fig. 1.15. Directed coupling of amino acids A and B 
I 	 II 	 III 
A+B C+D 	A+B C+D 
AB+CD 	 AB+C 	B+CD 
ABC +D 	A+BCD 
ABCD 	 JCD 	 AB D 
Fig. 1.16. Strategies for peptide synthesis 
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In SPPS the C-terminal residue of a peptide chain is bonded covalently to an 
insoluble, polymeric support (referred to as 'resin'). The peptide is built up by a 
series of coupling steps in which an activated Na-protected amino acid is reacted 
with the free amino group at the N terminus of the growing peptide, alternated with 
deprotection steps to remove the NOc protecting group. As the carboxyl terminal 
residue remains attached to the solid support throughout, the protecting group 
problem is reduced to the requirement for N 'temporary protecting groups' and 
'permanent protecting groups' for the side-chains. Because the peptide is bonded to 
the insoluble support, purification at each stage becomes a question of simply 
washing away the unreacted reagents and by-products. This in turn means that each 
reaction can be driven to completion, or near completion, by the use of a large excess 
of reactants. The resin is retained in a single reaction vessel throughout the 
synthesis, thus minimising mechanical losses. Finally, the highly repetitive nature of 
the coupling and deprotection steps means that the process is readily amenable to 
automation. At the end of the synthesis the peptide is 'cleaved' from the resin and 
the permanent protecting groups removed, generally a concerted process. 
The utility of SPPS was demonstrated by Merrifield in the early '60s by the synthesis 
of a tetrapeptide, Leu-Ala-Gly-Va160. 
1.2.2 Protecting Group Strategies 
In Merrifield's first solid phase synthesis, no side-chain protection was necessary, 
since the four amino acids chosen all have aliphatic side chains. The N protecting 
group used was the benzyloxycarbonyl (Z) group, which was removed by treatment 
with HBr in acetic acid, and the final cleavage from the resin was carried out with 
sodium hydroxide. Whilst this methodology was quickly changed to allow for less 
harsh conditions during the repetitive removal of the temporary protecting group, one 
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feature of the original Z group has been retained: all the major Ncc protecting groups 
are oxycarbonyls. 
The protection of Naas a urethane prevents racemization of the activated amino acid 
through oxazolone formation, which can occur if the amino function is protected with 
a acyl group (Fig. 1.17). The oxazolone readily loses a proton to give an aromatic 
species in which stereochemical integrity is lost. Under normal conditions, urethanes 
will not form oxazolones, possibly due to the lower acidity of the urethane proton 
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Fig. 1.17. Amide vs. urethane protection 
1.2.2.1 Boc Methodology 
The second N protecting group used by Merrifield 
61  was the t-butyloxycarbonyl 
(Boc) group62(3), which remains in widespread use today. The Boc group can be 
removed using a variety of acidic reagents, eg. 0. iN HC1/acetic acid, neat 
trifluoroacetic acid (TFA) or TFAIDCM in various ratios from 1:4 to 1:1. Initial loss 
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of the t-butyl cation is followed by spontaneous decomposition of the carbamic acid 
to free amine and CO2 (Fig. 1.18). 
HON 	 HN 
Co 
2 
Fig. 1.18. Deprotection of a Boc-protected peptide 
The greater stability of the t-butyl cation in comparison with the benzyl cation means 
that the Boc group can be removed under milder acidic conditions than the Z group. 
This in turn means that, when Boc is used for Naprotection, protecting groups based 
on the Z group, ie. benzyl esters, ethers and Z itself, can be used for side-chain 
protection, since these will be stable to the acid conditions used for N  deprotection 
throughout the synthesis. Final side-chain deprotection is carried out using very 
strong acid (usually liquid HF). 
Numerous Ncc protecting groups based on Boc have been developed, examples being 
t-amyloxycarbonyl (Aoc)63(4), adamantyloxycarbonyl (Adoc)(5), 2-(p- 
biphenylyl)propyl-(2)-oxycarbonyl 	(Bpoc)65(6) 	and 	a,a-dimethyl-3 ,5- 
dimethyloxybenzyloxycarbonyl (Ddz)66(7). 
In general, Aoc and Adoc have very similar properties to Boc. However, their 
derivatives have more favourable solubility characteristics and are more easily 
prepared due to the greater stability of the chioroformates, and therefore may be 
preferred under certain circumstances. On the other hand, Ddz and Bpoc were 
designed to be far more acid labile than Boc. The relative deprotection rates in 0.5% 
TFAIDCM are" Boc:Ddz:Bpoc 1:2.3x104:1.3x105. Therefore Bpoc and Ddz can be 
used in conjunction with t-butyl-derived side-chain protecting groups, allowing for a 





















1.2.2.2 Fmoc Methodology 
The 9-fluorenylmethyloxycarbonyl (Fmoc)68 N protecting group allows a truly 
orthogonal approach to SPPS as it is stable to acid and catalytic hydrogenation, but is 
removed on treatment with mild base (20% piperidine/DMF) by a 3-elimination 
mechanism (Fig. 1.19). Thus Fmoc temporary protection can be combined with t-
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Fig. 1.19. Deprotection of an Fmoc-protected peptide 
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The dibenzofulvene deprotection intermediate is trapped by excess piperidine, 
preventing it from reacting with free amine, and giving an adduct which has a strong 
absorbance at 300nm. This forms the basis of a system for monitoring the success of 
the synthesis, as the extent of coupling of each residue can be calculated from the UV 
absorbance of the filtrate after each deprotection69. 
Boc Methodology Fmoc Methodology 
-0O2H -0O2CH2Ph -0O21Bu 
-OH -OCH2Ph -OtBu 
-NH2 -NHCO2CH2Ph -NHCO,tBu 
Table 1.2. Standard side-chain protecting group strategies for SPPS 
1.2.3 The Solid Support 
The most successful solid supports developed to date are the polyamides71' and 
copolymers of styrene with divinylbenzene (0.5-2%). Polystyrene resins are 
functionalised by chloromethylation. For a successful synthesis it is necessary that 
the resin swells effectively in the solvents used since the overwhelming majority 
(>99.9%) of the functional sites are located on the interior of the polymeric matrix7 . 
In the first solid phase synthesis the peptide was attached directly to the 
functionalised resin. However, the introduction of 'linkers' between the support and 
the peptide has allowed fine-tuning of the strength of the peptide-resin bond, so that 
it can be made more or less labile to suit the synthetic strategy. This is demonstrated 
by the linkers used in Boc and Fmoc methodologies (Fig. 1.20). In Boc methodology 
the peptide-linker bond is a benzyl ester, allowing it to be cleaved simultaneously 
with the side chain protecting groups during HF treatment. However, the Wang 
linker 
72 
 generally used in Fmoc methodology is cleaved by TFA along with the 'Bu- 
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derived protecting groups. In both cases the cleavage mechanism is an ester 
hydrolysis by alkyl-oxygen fission, rather than the more common acyl-oxygen 
fission. In the p-benzyloxybenzylalcohol (Wang) resin the additional p-oxygen helps 
to stabilise the carbocation formed during the fission process, thus increasing the 
lability of the peptide. 
The use of linkers also allows the functionality at the C-terminus of the cleaved 
peptide to be adapted to requirements. Resins are available that give peptide amides 
and peptide hydrazides under standard cleavage conditions. 
Boc methodology - PAM Resin 
N 
Pept.NH 
0 	 R 
OH 
10 	Pept.NH  
0 
Fmoc Methodology - Wang Resin 




Fig. 1.20. Acidolytic cleavage from the resin 
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1.2.3.1 Diketopiperazine Formation 
The benzyl alcohol moiety of the peptide-resin ester linkage is, under normal 
conditions, a poor leaving group in SN2  reactions. The only significant nucleophiles 
present during a synthesis are the free amino terminal groups of the growing peptide 
chain, and therefore during most of the synthesis the peptide-resin anchor is almost 
100% resistant to attack. However, at the level of the dipeptide, the amino terminus 
is uniquely positioned to undergo an intramolecular cyclization to form a 6-
membered diketopiperazine ring" (Fig. 1.21), effectively terminating the peptide 
chain. 
H 	 10 
Fig. 1.21. Diketopiperazine formation in the dipeptide Val-Pro-Resin 
Diketopiperazine formation is strongly sequence-dependent, as the transition state 
requires that the peptide bond adopt the, usually disfavoured, cis-conformation. For 
a given C-terminal residue the likelihood of the rearrangement occurring is in the 
order N-methyl amino acid>Pro>Gly>Val. In general the side reaction can be 
ignored as it occurs at a level of <5%, unless either of the first two residues is glycine 
or proline. 
1.2.4 Coupling 
The coupling of two amino acids always occurs by attack of the nucleophilic a-
amino function on an activated carboxyl function; there is no practical coupling 
method available that proceeds through an activated amino function. The degree of 
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activation controls the rate of coupling, but also the likelihood of side reactions, so 
that a delicate balance between the two must be maintained. 
At this point it is worth mentioning the reasoning behind the synthesis of peptides 
from the C- to N-terminus, rather than nature's way (N to Q. Since it is always the 
carboxyl group which is activated, in an N to C synthesis it is the growing peptide 
chain which will be activated. However, the N  group of the C-terminal residue in a 
peptide is effectively 'protected' by an acyl group, making it susceptible to 
racemization through the oxazo lone (see Fig. 1.17). Thus some racemization can be 
expected at every coupling step, and the racemized product is attached to the solid 
support, resulting in a purification nightmare for the final cleaved product. In a C to 
N synthesis, however, the activated species is the solution-phase amino acid. As has 
already been described, use of urethane-type protection in such a species effectively 
prevents racemization. In addition, should the activated amino acid undergo any 
rearrangement that prevents it from reacting, it will simply be washed away at the 
end of the coupling step, not, therefore, interfering in the synthesis. 
1.2.4.1 Acid Chlorides 
The most obvious method of forming an amide from a carboxylic acid and an amine 
is through the acid chloride. However, a urethane-protected amino acid chloride is an 
inherently unstable species, having a tendency to form N-carboxyanhydrides74 
(Fig. 1.22). In addition, the reaction conditions required for acid chloride formation 
and coupling are incompatible with 'Bu-based protecting groups, and therefore this 
method is not generally used in SPPS. 
H 	R H 	 H 	
R 
/ 
\ 	 / 	 4- RCI 
R 	 20 	
N 
Oct 	 0 
N-carboxyahydxide 
Fig. 1.22. Decomposition of a urethane-protected amino acid chloride 
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1.2.4.2 Mixed Anhydrides 
Three types of mixed anhydrides have been used in peptide synthesis, those of 
carboxylic acids, carbonic acids and phosphorous derivatives. 
0 	0 	 0 	0 	 0 	0 
0 	 R 	0 	\ Ph R 	 R 	0 	
Pb 
(8) 	 (9) 	 (10) 
Mixed anhydrides of carboxylic acids have two electrophilic sites which can lead to 
ambiguous nucleophilic attack. For this reason the main mixed anhydrides of this 
type used are the mixed pivalic anhydrides (8) in which both steric hinderance and 
the electron-donating inductive effect of the t-butyl group direct attack to the 
required carbonyl. In the carbonic acid mixed anhydrides (9) the carbonyl group that 
is not required to react is flanked by two oxygens, thus decreasing its reactivity and 
increasing the regioselectivity of the nucleophilic attack. However, both these 
classes of mixed anhydride have a major disadvantage as far as SPPS is concerned: 
they must be used at low temperatures (-20°C to -5°C) as they have a tendency to 
disproportionate, and commercial peptide synthesisers are designed to operate at 
room temperature. The mixed carboxylic-phosphinic anhydride (10) circumvents 
both these problems, being far more stable at ambient temperatures and undergoing 
nucleophilic attack exclusively at the carbonyl. 
1.2.4.3 Symmetrical Anhydrides 
Symmetrical anhydrides have the advantage over mixed anhydrides that there is no 
possibility of chain termination due to opening of the anhydride the 'wrong way'. It 
is an expensive method, as half the protected amino acid species is unused, but is 
nonetheless useful in SPPS as the highly activated species couples very rapidly"'. 
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Symmetrical anhydrides are generally preformed immediately before use, by the 
action of a carbodiimide on two equivalents of the protected amino acid. Originally 
dicyclohexylcarbodiimide (DCC) was used for this purpose, but the current reagent 
of choice is diisopropylcarbodiimide (DIC) since the by-product of the reaction, 
diisopropylurea, is fully soluble in the solvents used in SPPS (Fig. 1.23). 
Side-chain-unprotected asparagine and glutamine cannot be coupled by this method, 
as their amide groups are susceptible to dehydration to a nitrile functionality by both 
DCC and DIC (Fig. 1.24). 
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Fig. 1.23. Formation of a symmetrical anhydride by the action of DIC 
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Fig. 1.24. Dehydration of asparagine by the action of DIC 
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1.2.4.4 Activated Esters 
The coupling rates of activated esters are considerably lower than those of the 
symmetrical anhydrides, but they have the advantage that none of the amino acid 
derivative is 'wasted'. Activated esters have been used extensively in solution-phase 
peptide chemistry, the phenyl esters in particular, eg. p-nitrophenyl76(1 1), 2,4,5-
trichlorophenyl77( 12) and pentafluorophenyl7 ( 13), having the the advantage that they 
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(14) (15) 
A second class of activated esters important in solution-phase chemistry comprises 
the derivatives of N-hydroxyphthalimide79( 14) and N-hydroxysuccinimide80( 15). 
Such N-acylhydroxylamines (or hydroxamic acids) are acidic compounds and their 
0-acyl derivatives could be thought of as mixed anhydrides. However, their 
reactivity is due rather to interactions between the incoming amine and the nitrogen 
atom of the leaving group (Fig. 1.25). 
0 	 0 	0 
RON\7 + RH2 
/1 	 R  
0 0 
Fig. 1.25. Interaction of an N-hydroxysuccinimide AE with an incoming amine 
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Despite the utility of the above reagents in solution-phase peptide synthesis, they 
were found to be ineffective in SPPS. Fortunately, however, it was discovered that 
1 -hydroxybenzotriazole (HOBt)', originally added to coupling reactions to prevent 
racemization, forms an activated ester which can be used successfully in SPPS. The 
HOBt derivative interacts with the incoming amine in an analogous fashion to the 
hydroxamic acid derivatives (Fig. 1.26). HOBt activated esters are preformed 
immediately before use in the presence of one equivalent of DIC (Fig. 1.27). 
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Fig. 1.27. Formation of an HOBt activated ester by the action of DIC 
The success of HOBt in SPPS has lead to the development of improved analogues, 1-
hydroxy-7-azabenzotriazole (HOAt)82 (16) and ethyl-i -hydroxy- 111-1,2,3 -triazole-4-
carboxylate (HOCt)83 (17). 
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In the search for a therapeutic strategy for the combat of rheumatoid arthritis, IL-i 13 
appears to be a good target since it has been shown to effect many of the pathologies 
of the disease. Intervention could concentrate on blocking the binding of IL-i 13 to its 
receptor; trials involving the use of IL-ira to such an end have been carried out". 
However, due to the low receptor occupancy required for IL-i13 to exert its effect, 
very large excesses of a receptor antagonist would be required for successful 
treatment by this method. Since IL-l13 is biologically inactive in its precursor state, 
inhibiting the IL-113 converting enzyme (ICE) should effectively prevent those 
symptoms arising from the action of extracellular IL-1. 
Considerable effort has been expended in the search for a small, non-peptidic 
inhibitor of ICE. To date none has been reported. Therefore the aim of this work has 
been to attempt to establish factors of importance for substrate recognition by ICE, 
beyond those found in previous work 43 '45 (see section 1.1.6), by the use of solid 
phase peptide synthesis. 
The work has been concentrated in three areas, the cleavage region of prolL-i 13, the 
cowpox inhibitor crmA, both of which are known to interact with ICE, and the pro 
region of ICE itself, which may be important for correct folding of the enzyme. 
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2.2. ProIL-113 Peptides 
Inspection of the crystal structure of mature IL-l13 reveals that the residues 
immediately following the cleavage site form a 13 -sheet with residues from 13-strand 4 
(see Fig 1.2). It was decided to attempt the synthesis of a peptide incorporating both 
the cleavage site and the relevant strand 4 residues (160-163), the fragments being 
linked by a 13-turn-like segment. 
The 13 -turn is a common structural motif in proteins, being a tetrapeptide sequence 
which changes the direction of the peptide chain by 1800.  Several classes of 13-turn 
have been described, based on the torsion angles of the backbone residues 2 and 387 
(Fig 2.1). A hydrogen bond between the carbonyl oxygen of residue 1 and the NH of 





type 	2 	'V 2 	'V 3  
degrees 
I -60 -30 -90 0 
F 60 30 90 0 
II -60 120 80 0 
II' 60 -120 -80 0 
III -60 -30 -60 -30 
III' 60 30 60 30 
Fig 2.1. The structure of the 13-turn and the classification of the major types 
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In the first instance it was decided that the 1800  turn required in the test peptide could 
be fixed by the formation of a disulphide bond between two cysteine residues. In 
order to facilitate the formation of the S-S bond the Cys residues were to be separated 
by two amino acids, two glycine residues being chosen. 
The synthesis of KU 1, prolL- 1 113-1 22-CysGlyGlyCys- 160-163 (YVHDAPVRSL 
CGGCMSFV), was carried out using standard methodology, the cysteines being 
protected with the acid-labile trityl group, which is removed concurrently with 
cleavage from the resin. The synthesis was disappointing, with a large drop of >40% 
in the coupling efficiency of 10Leu, and a further decrease over the next three 
residues, so that the final Fmoc deprotection showed overall coupling of just 36%. 
Despite the poor synthesis an initial, small-scale cleavage gave some encouragement, 
resulting in two easily separable products, the required peptide and the expected main 
deletion product, CGGCMSFV. However, scale-up gave an altogether more 
complex crude product. It was assumed that this was due to dimerisation of the 
peptide, despite the fact that the work-up was carried out using solvents containing 2-
5% dithiothreitol (DTT) in an attempt to keep the free thiols in their reduced state. 
Oxidation to the cystine-containing peptide also proved difficult. Simple air 
oxidation at low peptide concentration resulted in no discernible change in the 
analytical HPLC. A DMSO oxidation" was attempted, though this was risky given 
the presence of a highly oxidation-sensitive methionine residue. 	Perhaps 
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unsurprisingly, treatment of the peptide with DMSO resulted in an unworkably 
complex mixture of products, as shown by analytical HPLC. In view of the problems 
with the synthesis, cleavage and oxidation, this synthesis was abandoned. 
On repeating the synthesis it was decided to employ cysteine protecting groups 
which could be removed independently of the other side-chain protection, and hence 
the tert-butylsuiphenyl (S'Bu) group was chosen. In addition the two glycine 
residues were replaced by proline-D-valine, a dipeptide unit known to favour the 
formation of type II' 3-tums89, as it was thought that this might facilitate the 
oxidation step. The synthesis of KU2 was carried out as before, except that six 
residues, 8Arg-13D.Val, were given extended coupling times in order to try to avoid 
the drop in coupling efficiency seen previously, and because the behaviour of the 
peptide containing the 3-turn-inducing residues was unpredictable. This strategy was 
successful, the coupling efficiency of the penultimate residue being 99%. 
It has been reported that cyclisation of a dicysteine-containing peptide can be 
accomplished whilst the peptide remains anchored to the solid support". This 
methodology takes advantage of the phenomenon of pseudo-dilution: whilst a 
peptide chain is attached to the resin it is effectively unable to interact with other 
peptides and hence can only react intramolecularly. The removal of S'Bu groups 
from the resin-bound peptide was carried out by treating preswollen resin with 
tributylphosphine for 5-23 hours. Cleavage of treated resin showed that up to 50% of 
the peptide was fully deprotected; however, it was extremely difficult to obtain 
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reproducible results. The oxidation method described by Eritja et a19° involved the 
treatment of DMF-swollen resin with an aqueous solution of potassium ferricyanide. 
However, most of the potassium ferricyanide appeared to precipitate on contact with 
the DMF, and perhaps unsurprisingly no oxidation was seen. In view of the 
difficulties experienced, the method was not pursued. 
Fortunately the procurement of the required peptide by conventional methods proved 
far easier. Cysteine-protected KU2 was readily purified by preparative HPLC, and 
subsequent removal of the S'Bu groups was completed in 2.5 hours by treatment with 
tributyiphosphine. The oxidation was carried out cleanly by an air oxidation in 
aqueous buffer at pH8-9. A low concentration, ling in lOmi, was used to prevent 
dimerisati on91. 
Whilst the synthesis of KU2 was successful, the formation of the disulphide bond 
was both time-consuming and costly in terms of the mechanical losses associated 
with the sulphur deprotection and oxidation steps. Clearly, therefore, it would be 
advantageous if a single entity could be found which could be introduced into the 
peptide chain during synthesis, and which would promote the required 1800  change 
of direction, namely a 13-turn mimic. 
Unlike the major types of 13-turn (1,11 & III and their inverses) in which all the 
peptide bonds are of the usual trans type, the typeVl turn contains a sterically less 
favourable cis peptide bond between residues 2 and 3. Paul et ar2 have suggested 
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that a pyroglutamic acid residue functionalised at C7 with an amino group cis to the 
carboxylate (Fig 2.2) may act as a 13-turn mimic, since modelling studies indicate that 
such a molecule adopts a conformation with 4' and  w values typical of a type VI turn. 
On the basis of these observations it is proposed that a simple cyclopentane ring 
system, bisubstituted with an amino and a carboxylic acid group may also act as a 
type VI 13-turn mimic. It is expected that the pseudo-diequatorial form of cis-
aminocyclopentane- 1 -carboxylic acid (ACPC) would be energetically favoured 
compared with the pseudo-diaxial form; however, on incorporation of ACPC into a 
peptide, hydrogen-bonding interactions between the two strands of a 13-sheet 
structure should increase the stability of the diaxial conformation (Fig. 2.3). In 
addition, it is suggested that the flexibility of the system may give it an advantage, in 
certain situations, over other, more rigid 13-turn mimics which have been described in 
the literature". The nature of interactions of peptides and proteins with enzymes and 
receptors is such that the conformation of the protein in solution may be different 
from its conformation in the bound state. Therefore, a degree of flexibility in the 13-





Fig. 2.2. Functionalisation of a pyroglutamic acid residue to produce a potential 










Fig 2.3. cis-3-aminocyclopentane-1-carboxylic acid (ACPC) - a proposed type 
VI 13-turn mimic. 
As the 13-turn mimic, ACPC, is a 13-amino acid it is amenable to insertion into 
peptides via standard Fmoc methodology. The Fmoc derivative was obtained in two 
steps, by the hydrogenation of cis-3-aminocyclopent-4-ene-1-carboxylic acid, 
followed by Fmoc protection of the amino group by treatment with 9-
fluorenylmethyl succinimidyl carbonate in the presence of base (Fig. 2.4). 
± 	 + 
H3Nc02 	 113N 	 co 
0 
i) H2 ,Pd/C 	 ,Et3N 	iii) aq HC1 
Fig. 2.4. Synthesis of FmocACPC 
The synthesis of KU3, prolL-1131 13-122-ACPC-160-163, was the first to employ 
FmocACPC. Therefore the first few residues, up to and including the leucine residue 
coupled to the ACPC-peptide-resin, were coupled manually using bubbler apparatus. 
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This allowed the coupling of each residue to be checked by a Kaiser test before Fmoc 
deprotection to ensure a quantitative synthesis. Coupling of FmocACPC was carried 
out using the HOCt activated ester. This coupling reagent was developed in this 
laboratory, and has been shown to give faster, more efficient couplings than HOW'. 
The Kaiser test revealed 100% coupling after a single, overnight treatment. The 
synthesis was completed automatically and analytical HPLC of the crude product 
showed a very efficient synthesis. Simple preparative HPLC gave the required 
peptide. 
In order to be able to establish the effect of the imposed n-sheet structure on the 
recognition of KU2 and KU3 by ICE, it was decided that the peptide comprising only 
the cleavage region of prolL-1 P should be synthesised. Therefore the 8-mer, prolL-
1 J3 113-120 (KU4), which has been shown to be the optimum small peptide substrate 
of ICE43, was synthesised using standard techniques. 
Whilst it is known that a cleavage site peptide substituted with a glutamic acid 
residue at the P1 (Asp) site is a poor substrate for ICE (see Fig. 1.5), no K1 value 
showing the ability of such a peptide to act as an inhibitor of ICE has been published. 
Therefore the peptide proIL-1 P 111-122 116Glu was synthesised for comparison of its 
inhibitory efficacy with that of prolL- 1 111-122 itself, as synthesised in this 
laboratory by D Maclean". 
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Whereas the crucial residue for recognition of the prolL-1 13  processing site by ICE is 
aspartic acid, the majority of known prohormones and propeptides are cleaved C-
terminal to a pair of basic residues (arginine and/or lysine). However, just as ICE 
does not cleave at all Asp residues, enzymes such as trypsin do not recognise all 
dibasic sites. There is evidence that propeptides are cleaved at dibasic sites that are 
immediately preceded by 13-turns", although whether the type of turn is important has 
not been elucidated. This raises the possibility that some secondary structural 
element is also important for processing site recognition by ICE. Thus it is 
interesting that both the sites at which prolL-1 13  is cleaved, Asp27-01y28 and 
Aspll6-A1a117, are immediately succeded by proline, a residue known to encourage 
the formation of 13-turns. Changing the configuration of an amino acid residue will 
inevitably change the conformation of a 13-turn in which it is involved. Therefore the 
peptide prolL-1 1311 1-122 "9D.Val (KU6) was synthesised in an attempt to discover 
whether the secondary structure in this region is of importance. 
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Table 2.1. ProIL-113 Peptides 
2.3. CrmA Peptides 
The reactive site loop (RSL), through which serpins bind to and inhibit proteases, is a 
flexible region in an otherwise structurally well-defined molecule". Thus it seems 
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likely that the conformation required for inhibition is induced on complexation of the 
serpin with the enzyme. Therefore it was of interest to discover whether a short 
peptide representing the RSL of CrmA, and almost certainly being inherently 
unstructured, would be recognised by ICE, and if so whether it would act as a 
substrate, or as a true inhibitor. 
Sleath et a!43 found the peptide comprising the four residues on each side of the 
proIL-1 P cleavage site (P4-P4') to be preferred as a substrate of ICE compared with 
both longer and shorter sequences. Therefore in the first instance the 8-mer 
corresponding to these residues in the RSL, CrmA 300-307 (KU7), was synthesised. 
In this sequence the P1 Asp is followed by a cysteine residue. The preferred P1 ' 
residue in ICE substrates is Ala or Gly. It seems possible, therefore, that the cysteine 
is involved in the inhibitory process in some way. To test this theory a second 8-mer 
(KU8) was synthesised, in which the order of the P1 ' and P2' residues, CysAla, was 
reversed, creating a classic ICE recognition site. It was hoped that, if inhibition were 
seen with CrmA 300-307, this change would result in restoration of substrate 
activity. 
Finally a slightly longer peptide, CrmA 298-309 (KU9), was synthesised. There 
were several reasons for this. Firstly, it was hoped to see whether variation in length 
affects recognition in an analogous fashion to that seen for fragments of prolL-1 P. 
Secondly, the longer peptide contains a second Cys residue at the P6 position. It was 
hoped that it would be possible to oxidise the peptide to form a disulphide bond 
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between this and the P1 ' cysteine, thus imposing structure on it. If the imposed 
structure resembled that of the inhibitory conformation of the RSL then improved 
inhibition might be seen. Additionally, since the structure of CrmA is unknown, it is 
not certain whether the Cys residue at the P1' position exists as a free cysteine, or is 
involved in a disulphide bond. Therefore it was thought possible that the oxidised 
peptide might have different inhibitory/substrate properties compared with the 
reduced form. Finally, cyclic peptides are often more stable than their linear 
analogues, having enhanced resistance to proteolytic degradation". 
AcLVADCAST-NH2 	KU7 
AcLVADACST-NI-12 KU8 
AcCALVADCASTVT-NI 2  KU9 
Table 2.2. CrmA Peptides 
The synthesis of KU7 was rather disappointing, the estimated final coupling 
efficiency of about 50% being poor for such a small peptide. Clearly the sequence is 
a difficult one. Therefore for the synthesis of KU8 the final five residues were given 
extended coupling times, and the most problematic residues, 'Leu and 5Ala, were 
triple coupled. The synthesis was interrupted before removal of the final Fmoc so 
that the extent of coupling could be checked manually. This revealed that the 
coupling efficiency for the leucine was just 57%. This residue was therefore 
recoupled as the HOCt activated ester, a strategy which had been found to improve 
the synthesis of other difficult sequences". However, in this case no improvement 
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was seen in the coupling efficiency. Finally, the resin was sonicated with 4 
equivalents of the Fmoc-leucine HOBt activated ester, overnight. This brought the 
final coupling efficiency to a more acceptable >90%. 
The longer CrmA fragment was initially synthesised as the 13-mer, CrmA 297-309, 
AcThrCysAlaLeuValAlaAspCysAlaSerThrVal ThrNH2 (KU 10). The 12-mer, CrmA 
298-309, has an N-terminal cysteine residue. These can sometimes be problematic, 
leading to facile dimerisation of the peptide. However, the synthesis of KU 10 was 
poor, with a significant drop (30%) in coupling efficiency over the internal residues 
7 
 ASP_ 5Val, and a disastrously poor coupling of the final threonine residue. In 
particular, it would have been difficult to separate the required peptide from the des-
'Thr deletion peptide by preparative HPLC. Therefore the synthesis was repeated, 
omitting the final Thr residue, and extending the coupling times of the problematic, 
central residues. 
Problems were also encountered during the purification of these peptides. Since 
KU7 and KU8 contained free thiol groups, dithiothreitol (2-5%) was added to all 
solvents used in the cleavage work-up and when dissolving samples for HPLC, in 
order to prevent dimerisation. The crude peptides were very insoluble which made 
preparative HPLC difficult. Prior to injection onto a semi-preparative HPLC 
column, a peptide must be dissolved at a concentration of 5-10mg/ml. Various 
combinations of water, acetic acid and acetonitrile were tried, without success. 
Eventually it was discovered that the peptides could be dissolved satisfactorily by 
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suspending them in aqueous 6M guanidine hydrochloride and adjusting the pH to 
between 8.5 and 9 by the addition of solid Trizma Base (Sigma). For KU7, 
preparative HPLC was carried out using both the standard, acidic buffer system and a 
basic buffer system comprising Buffer A: 50mM aqueous ammonium acetate, pH8.5; 
Buffer B: 10% A!acetonitrile. As the standard TFA buffered system gave more 
satisfactory results, this was used throughout the purification of the remaining 
peptides. 
The two 8-mers contained only one cysteine residue apiece, and the trityl (Trt) 
protecting group, which is removed on TFA cleavage, was used for these. However, 
as the 1 2-mer, KU9, contains two cysteine residues, and in particular an N-terminal 
one, it was felt that it would be advisable to be able to control the removal of the 
cysteine protection. Since the sequence in question proved to have such low 
solubility, the synthesis of KU9 was carried out using the solubilising 
acetamidomethyl (Acm) protecting groups, rather than the very hydrophobic tert-
butylsulphenyl (S'Bu) group (Fig. 2.5). 
-so 	
0 
Cys-Trt 	 Cys-StBu 	 Cys-Acm 
Fig. 2.5. Standard cysteine protecting groups used in Fmoc methodology 
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The Acm group can be removed by reagents such as metal ions, Hg" and Ag', which 
give the reduced peptide, and iodine, which removes the protecting group with 
concomitant oxidation to the disulphide bridged peptide. 
The pure cysteine-protected peptide was obtained by preparative HPLC followed by 
lyophilisation. Acm removal was initially attempted using Hg" ions. The peptide 
was dissolved in 30% acetic acid and stirred overnight with 40 equivalents of 
mercuric acetate. 3-mercaptoethanol was added to remove the mercury ions and the 
mixture filtered and chromatographed. However, the recovered material was 
exclusively the bis-Acm protected peptide. 
The second reagent tried was cyanogen iodide, which has been found both to remove 
Acm protecting groups and to oxidise the peptide in a single step. The peptide was 
stirred with 50 equivalents of ICN in 50% aqueous methanol, in the dark, overnight, 
the reaction being quenched by the addition of sodium thiosuiphate. Analysis of the 
recovered material revealed that the major portion was bis-Acm-protected peptide, 
with a very small amount of mono-Acm and several unidentified products. 
Treatment with silver trifluoromethanesulphonate (silver triflate) resulted in a 
product which was exclusively the fully deprotected peptide; however, the recovery 
was initially very poor and required considerable optimisation. The reaction was 
carried out in the dark. The peptide and 20 equivalents of silver triflate were cooled 
on ice before the addition of TFA. The reaction was followed by HPLC and the 
optimum reaction time found to be 2.5 hours. Most of the TFA was then removed in 
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vacuo and a solution of dithiothreitol (DTT) (100 equivalents) added to liberate the 
peptide from its silver salt. In standard methodology the peptide silver salt is 
precipitated by the addition of ether before being redissolved in DTT in 50% aqueous 
acetic acid. However, due to the low solubility of the peptide, it was found that the 
yield was improved if the peptide silver salt was not precipitated. As has been 
mentioned previously, the solubility of the peptide is greater in basic, rather than 
acidic, solvents. Therefore the DTT was dissolved in tris buffer at pH8 and added to 
the slurry produced by removal of most of the TFA. It was thought that the peptide 
might be adhering to the glassware; therefore the flask was silylated prior to the start 
of the reaction, and, on removal of the TFA in vacuo, care was taken to avoid 
evaporating the flask to dryness. The peptide was stirred in the DTT solution 
overnight, which resulted in the formation of a yellow precipitate, the silver-DTT 
complex. This was removed by centrifugation and the peptide in the supernatant was 
purified directly by preparative HPLC. To improve recovery the pellet was 
resuspended in 6M guanidine HC1, brought to pH8 by the addition of tris base, and 
recentrifuged, the supernatant again being subjected to preparative HPLC. This 
procedure was repeated, but analytical HPLC of the supernatant showed that no 
further peptide had been liberated from the pellet. By using this optimised procedure 
the yield of fully deprotected peptide was approximately 50%. 
Disulphide formation was carried out by a simple air oxidation in ammonium acetate 
buffer. 
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2.4. The Pro-region of ICE 
Many enzymes, like ICE, are expressed as proenzymes, which undergo proteolytic 
processing to give the active species. For such enzymes the pro-region can be 
important for direction of the correct folding of the molecule. Additionally it may be 
that the cell stores certain enzymes in their precursor state, proLessing them only as 
required, thus allowing a rapid response to external influences. For some enzymes, 
for example subtilisin, it has been shown that the pro-region, once it has been cleaved 
from the mature enzyme, acts as an inhibitor of the enzyme itself". Such a 
mechanism might be important in the feedback control of enzyme activity. 
The pro-region of ICE is 119 amino acids long, and itself contains a secondary 
cleavage site, between Asp103 and Ser104, which gives rise to the alternatively 
processed fragment, p22, which, like p20, can combine with plO to give an active 
enzyme (Fig. 2.6). 
Mltocatalytic processing 
p20 	 P 10 
, W_A2.e~_ 
Iactive Ienzyme - - 
Fig. 2.6. Alternative processing of proICE 
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To try to test the theory that the pro region might have inhibitory activity against 
ICE, it was decided to synthesise the entire 119 amino acid sequence. This would 
also give an opportunity to try out methodology for the synthesis of large peptides 
being developed in this laboratory. 
The initial plan was to synthesise the peptide by the fragment condensation of four 
smaller peptides, ranging in size from 22 to 45 residues (Fig. 2.7). This would have 
the added advantage that the shorter peptides could be tested individually for activity 
against the enzyme, thus showing whether any inhibitory activity resided in one 










Fig. 2.7. Proposed fragments for the synthesis of the ICE pro-region 
The fourth fragment, 89-119, was synthesised by standard methodology on Wang 
resin (KU 1 1). The synthesis was somewhat disappointing, with an overall coupling 
efficiency of just 50%. However, the cleavage and purification were straightforward, 
so that a reasonable yield was obtained. Examination of the deprotection profile for 
the synthesis showed that the poor couplings occurred at 
8  Gly, 26  Pro and 29Val (Fig. 
2.8), residues immediately following Asn and Gln residues. In this synthesis, Asn 
and Gln were coupled as their side-chain-unprotected species. As it is known that the 
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use of side-chain-unprotected Asn and Gin can sometimes result in poor coupling of 
subsequent residues, it was decided that, in future ICE pro-region syntheses, side-
chain protection would be used. 
DO VA OP A P F S S LV GQ SD QMN L V N G ST 0 DA S L 
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Fig. 2.8. Deprotection profile for KU61 - fourth fragment of the ICE pro-region 
In this laboratory, chemical fragment condensations are carried out through the 
coupling of a peptide azide to the free N-terminal amine of a second peptide chain. 
The peptide azide is generated from a peptide-hydrazide by treatment with t-butyl 
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Fig. 2.9. Chemical fragment condensation 
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The required peptide-hydrazides can be generated directly on cleavage from the resin 
provided that the amino acid chain is built onto an appropriate linker. Such a linker 
has been developed in this laboratory" (Fig. 2.10). 
HN 	Boc 
	 Peptide NQ 
Boc 
Synthesis 
0 1"'Y NHI~z 
 
Peptide - NHNH2 
Fig. 2.10. Synthesis of a peptide-hydrazide using a dibenzosuberane linker 
The linker is coupled to aminomethyl resin in the form of a ketone. It is then reduced 
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Fig. 2.11. Preparation of hydrazide resin 
The third fragment, 66-88NHNH2 (KU12), was synthesised using Fmoc-Gly-
hydrazide resin prepared and loaded by David Pallin. The Gln residue was protected 
using the 4,4'-dimethoxybenzhydryl (Mbh) group, whilst the Cys residues were 
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protected using a recently developed group, phenylacetamidomethyl (Phenac)'°°"°', 
which can be removed by the enzyme penicillin acylase. 




0 	OMe 	 0 	 0 
	
Gin-Mbh 	 Cys-Phenac 	 Cys-MeOPhenac 
The deprotection profile showed a large drop in coupling efficiency for the coupling 
of 11  Ile, the residue following the first Cys-Phenac moiety. Therefore 3Aia and 611e, 
which follow the remaining cysteines, were given extended coupling times. 
(18) 
An initial attempt was made to purify KU12 using the ThFmoc (17-
tetrabenzo [a, c,g, i]fluorenylmethoxycarbonyl) group102"13 (18). This affinity-based N-
a protecting group is coupled to the fully synthesised peptide before cleavage from 
the resin. The group has a high affinity for porous graphitised carbon (PGC). 
Therefore the required peptide, labelled at the N-terminus with TbFmoc, can be 
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separated from the deletion peptides by passing a solution of the crude peptide down 
a PGC column. The deletions are washed straight through whilst the full-length 
peptide adheres to the colunm. Because of its structural similarity to Fmoc, TbFmoc 
can be cleaved from the peptide by a base such as piperidine. Therefore the purified 
peptide is recovered from the PGC column by washing with 10% piperidine in, say, 
50% iso-propanol/6M aqueous guanidine HC1. 
Although a TbFmoc loading test showed that the group had been coupled 
satisfactorily to the resin-bound peptide, analytical HPLC, with monitoring at 
364nm, showed little TbFmoc-peptide. (TbFmoc has a characteristic strong 
absorbance at this wavelength.) It appeared that the peptide itself was quite 
insoluble, and that the addition of the very hydrophobic TbFmoc group exacerbated 
this. Thus very little of the TbFmoc-peptide was getting into solution and it therefore 
could not be detected by HPLC. Clearly the proposed affinity chromatography will 
not work unless the crude peptide can be fully solubilised. Straightforward 
preparative HPLC of the non-TbFmoc crude peptide resulted in very poor recovery, 
suggesting that insolubility was a problem even for the free amine. 
It was decided to resynthesise the peptide, but to change the cysteine-protecting 
group to 4-methoxyphenylacetamidomethyl (MeOPhenac). Ordinary TFA cleavage 
leaves the entire protecting group intact, but subsequent treatment with 
trifluoromethanesulphonic acid (TFMSA) should remove the methyl group, giving 
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improved solubility characteristics to the peptide and making the protecting group 
more susceptible to enzyme cleavage compared with Phenac10 "°4 
However, before this repeat synthesis could be carried out, a new batch of hydrazide 
resin had to be prepared. The preparation was carried out as previously, using 
aminomethyl resin obtained from another source. However, on attempting to carry 
out an automated synthesis it was found that the resin contained a large quantity of 
"fines", which blocked the filters, making the synthesis impossible. A similar 
problem was encountered with subsequent batches of resin from different 
commercial sources. Clearly a consistent supply of resin was hard to obtain and 
therefore we decided to try a different resin system. 
A quantity of PAM resin, preloaded with various N-a Boc-protected amino acids, 
was available in the laboratory (Fig. 2.12). 
0 
Boc N 
Fig. 2.12. Boc-amino acid-PAM Resin 
Therefore, after removal of the Boc group by treatment with 90% TFA/1-120, the 
linker was loaded onto this resin, by overnight treatment with the HOCt activated 
ester. Quantitative Kaiser tests showed that this coupling proceeded in >99.5% yield. 
Under the procedure for aminomethyl resin, the ketone is reduced to a hydroxyl 
function using LiBH4 (6 equivalents) in refluxing THE However, these conditions 
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were found to be too harsh for use with the PAM resin since the reducing agent had a 
tendency to attack the ester function also, resulting in loss of the linker. Therefore 
the conditions were modified to use a single equivalent of LiBH4 at room 
temperature. In order to optimise the coupling it was found that reaction with t-
butylcarbazate should be carried out as soon after the reduction as possible. The 
coupling of the Boc-hydrazine proceeded smoothly. 
In order to test the resin, a 5-mer, LIFAG-NHNH2 (KU 13), was synthesised manually 
using bubbler apparatus. The synthesis went well, and, as expected, analytical HPLC 
of the crude cleaved peptide showed a single product which gave the correct 
molecular weight by FAB mass spectrometry. 
At this stage, however, time was running short. Therefore it was decided to attempt 
the synthesis of the entire ICE pro region, linearly. 
A trial synthesis (KU14a) was carried out on a O.lmmole scale, ie. the peptide was 
synthesised rapidly using single coupling (symmetrical anhydride) throughout. This 
enables any problem areas of the sequence to be identified so that appropriate action 
can be taken during the repeat synthesis. Encouragingly, the trial synthesis finished 
with an overall coupling efficiency of 25% (see Fig. 2.13). Four areas were 
identified where coupling appeared to be problematic; therefore, during the second 
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Fig. 2.13. Deprotection profiles for the syntheses of the ICE pro-region 
)- 
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The largest drop in coupling efficiency was seen between 63P and 621  It was decided 
that some of the resin (approximately one third) should be removed after the coupling 
of 63P (marked by an arrow in Fig. 2.13). This would allow the isolation of the C-
terminal half of the pro region so that it could be tested alone for inhibitory activity 
against ICE. Moreover, by reducing the quantity of resin in the reaction vessel, the 
remaining peptide chain would be subjected to a greater number of equivalents of 
each activated amino acid, thus increasing the likelihood of a good coupling. In 
addition to the actual deprotection profiles as recorded during the syntheses, the 
lower part of Fig. 2.13 also shows an estimate of the actual coupling percentages, ie. 
the values which would have been recorded had a third of the resin not been 
removed. 
Inspection of the deprotection profiles shows an erratic rise and drop in the coupling 
percentages between '°4S and 99L which is reflected in the two sets of data. Such 
abnormal changes in the apparent coupling can be caused by variations in the 
swelling of the resin which depend on the length and sequence of the growing 
peptide chain. The extended series of coupling percentages of >100% seen for 
KU14a is probably due to a solvent delivery fault: if a smaller volume of 20% 
piperidine/DMF than normal is delivered, the resulting concentration of the Fmoc-
piperidine adduct in the solution sent to the LTV detector will be higher than it should 
be, resulting in an abnormally large peak area, and hence an overestimate of the 
coupling efficiency. 
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Fig. 2.14. Purification of KU151 using TbFmocIPGC methodology 
a) before and b) after PGC treatment 
Colunm C; FR imi/min; Loop 2m1 
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TbFmoc was coupled to the completed peptide as normal. After cleavage the full 
length peptide was separated from the deletion products by treatment with porous 
graphitised carbon (PGC). After washing the PGC column several times to ensure 
that all the deletions were removed, the required peptide was washed from the 
column with 10% piperidine in iso-propanol/6M guanidine HCI (1:1). The solution 
was then desalted by gel filtration to give the cysteine-protected peptide. 
Initially the resin cleavage was carried out using aqueous TFA conditions for 6 
hours. Lyophilisation gave a jelly-like peptide which was extremely insoluble, 
suggesting that the peptide had not been fully deprotected. The cleavage protocol 
was changed to a two-step procedure in which the resin was first cleaved for 4 hours 
using the anhydrous trimethylsilyl bromide (TMSBr) cleavage mixture; then, 
following work-up, the resin and peptide were returned to the flask and treated with 
aqueous TFA for a further 2 hours. Amino acid analysis of the peptide obtained by 
this method suggested that it was the required product. However, a TOF MS gave a 
value of 15507.8, considerably higher than expected (13661.7 for the Cys-protected 
1 19-mer). This suggested that the Asn and Gin groups had not been fully 
deprotected, with an average of 8 Mbh groups remaining on each molecule. Since 
TMSBr conditions are known to be the best for the removal of Mbh groups, the 
cleavage protocol was changed once again, to a single-step, 6-hour, TMSBr reaction. 
The resultant product was more soluble than the products of the other two cleavage 
methods, suggesting that the peptide might well be fully deprotected. Unfortunately 
it has proved impossible to confirm this by TOF MS, because the peptide is difficult 
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to handle and does not give good spectra, despite numerous attempts using different 
matrices, etc. 
The peptide obtained from the PGC column gave rather a broad peak by analytical 
HPLC. It was thought that this might be due to partial removal of the cysteine 
protecting groups by the rather harsh cleavage conditions. It was decided to attempt 
to remove the cysteine protection to see whether any sharpening of the HPLC profile 
occurred, and to try to improve the solubility characteristics of a still somewhat 
insoluble peptide. The deprotection was carried out by treatment of the peptide with 
Hg" ions in 50% aqueous acetic acid. The HPLC profile following gel filtration and 
lyophilisation was still rather broad, but this was not surprising since such a large 
peptide will adopt multiple conformations. A quantitative Eliman's test showed that 
there were an average of 1.8 free thiols per molecule, suggesting either that the 
deprotection was not entirely successful, or that some disulphide bonds had been 
formed. The peptide was subjected to a glutathione shuffle, stirring in 1M tris buffer 
(pH8) containing 1M guanidine HCI and oxidised (0.3mM) and reduced (3mM) 
glutathione, but no change in the HPLC profile was seen over several days. 
2.5. The Enzyme Assay 
IL-i P converting enzyme (ICE) was over-expressed in E. coli by Dr David Giegel 
(Parke-Davis Pharmaceuticals, Ann Arbor, MI) and was sent to Edinburgh on dry ice 
in the form of crude cell lysates. 
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Enzyme activity was measured with a fluorescence assay, employing the substrate 
AcYVAD-7-amino-4-methylcoumarin (AMC) (1). ICE cleaves specifically between 
the Asp residue and AMC moiety, resulting in an increase in fluorescence which can 
be measured against time. Such an increase could be clearly seen in control 
experiments involving only enzyme and substrate; however, the addition of test 
peptides, including those known to be substrates of ICE (e.g. KU84 and prolL-1 3 
111-122 (DML124) synthesised by D Maclean"), resulted in no change in the 
recorded time course. This suggested that for some reason the peptides were not 
acting even as competitive substrates of the enzyme. 
It was thought that other proteases present in the crude lysate might be destroying the 
test peptide. Therefore the assay was carried out using some affinity-column-
purified enzyme (also provided by D Giegel). The peptides once again failed to 
show any substrate activity. Another possible reason for the failure of the peptides 
was that they are produced as their TFA salts. Since the TFA can coat the peptide 
backbone in an unpredictable manner, it was thought possible that it might be 
interfering with the interaction of the peptide with the enzyme. An attempt was made 
to desalt some of the peptides by gel filtration (G15 Sephadex) followed by dialysis. 
Again this had no effect on the assay results. 
In order to try to ascertain whether any of the peptides were indeed acting as 
substrates, an HPLC assay was carried out. The peptide DML124 was incubated at 
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30°C for various times, then injected onto an HPLC column. Little change could be 
seen in the HPLC profile, even when the assay mixture was incubated overnight. In 
order to check that the products of enzyme cleavage would be clearly seen with the 
assay gradient used, the expected fragments, prolL- 113111-116  (KU 15) and prolL- 113 
117-122 (KU16), were synthesised, and injected onto the assay column. This 
showed that they would be clearly visible, eluting earlier than the unproteolysed 
peptide. 
These results were rather puzzling. Therefore it was decided to send the test peptides 
to our collaborators in the USA, to see whether more favourable results could be 
obtained. The enzyme inhibition assay used at Parke-Davis was essentially the same 
as that used here, except that the substrate used was AcYVAD-p-nitroaniline (2) with 
UV/vis detection. The results obtained showed that little or no inhibition could be 
observed with any of the test peptides (Table 2.3). 
The assay is run in the presence of a dithiotbreitol (DTT) concentration of 10mM, 
which is sufficient to disrupt most disulphide bonds; thus both KU9-oxidised and 
KU2-oxidised are almost certainly reduced by the assay buffer. 
The crmA peptides, KU7 and KU9, do seem to show a slight inhibitory effect. 
However, as ICE is a cysteine protease, and both the test peptides contain free 
cysteine side-chains, the inhibition seen could be a nonspecific thiol effect. 
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% Enzyme Activity at 
Peptides 	 125tM Peptide Conc. 
KU2 - oxidised 
prolL- 1 3 113-1 22-CysProD.ValCys- 160-163 100.05 
KU3 
proIL-1 	113-122-ACPC-160-163 97.13 
KU4 
proIL-1 	113-120 103.07 
KU5 
proIL-1 	111-122 116Glu 107.23 
KU6 
proIL-1 	111-122 "9D.Val 105.61 
KU7 
crmA. 300-307 95.04 
KU8 
crmA 300-307 304 Ala 305Cys 101.40 
KU9 - reduced 
crmA 298-309 89.27 
KU9 - oxidised 93.53 
KU11 
ICE pro-region 89-119 106.09 
KU14 
ICE pro-region 1-119 100.00 
Table 2.3. Enzyme assay results 
2.6. gp120 Peptides 
In order for the human immunodeficiency virus (HIV)-1 to infect CD4-positive 
lymphocytes, the virus envelope glycoprotein, gpl20, must interact with CD4. Five 
gpl20 residues important for CD4 binding have been identified by site-directed 
mutagenesis: these are Thr257, Asp368, G1y370, Trp427 and Asp457'°5. A 32-
residue peptide, Gd, containing three of these residues, Asp368, G1u370 and 
Asp457, has been synthesised in this laboratory, and has been shown to act as a 
discontinuous epitope of gpl2O, and to bind to CD4" 
RVA 
The design of GC 1 utilises the fact that two cysteine residues close to the important 
Asp and Glu residues form a disulphide bridge in native gpl2O. GC  consists of the 
relevant sequences from the conserved C3 and C4 regions of gp 120, continuing as far 
as the cystine group. To facilitate formation of the disulphide bond, the two cysteine 
residues are separated by a valine residue (see Fig. 2.15). 













N S c-c 
G R 
G 	I 








N S c-c 
V 
Fig. 2.15. The design of GO 
The CysValCys moiety is believed to adopt the structure of a y-turn, thus causing the 
peptide chain to fold back on itself. However formation of the disulphide bond 
requires oxidation with DMSO, relatively harsh conditions which can result in poor 
peptide recovery. 
Following the successful use of the dipeptide ProD.Val to induce formation of a 
turn in KU2, it was decided to synthesise an analogue of GC 1 in which the 
CysValCys grouping was replaced by CysProD.ValCys. As expected this 
modification allowed the disulphide to be formed by a simple, clean, air oxidation. 
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A second analogue of GC 1 has been synthesised in which the entire f3/'y-turn region 
has been replaced by the proposed f3-turn mimic, ACPC. The use of this residue 
means that two steps in the synthesis of GC 1 and the analogue KU 17, namely 
deprotection of the cysteine residues and oxidation, can be eliminated. The result is 
that a higher yield of peptide can be obtained in a shorter time. 
At the time of the synthesis of the ACPC analogue, KU18, a limited amount of 
FmocACPC was available. Therefore the synthesis was carried out on a slightly 
smaller scale than usual (0.2mmole) and, in order to ensure that coupling of the 
ACPC residue was as complete as possible, it was coupled manually, with 
sonication, overnight as the HOCt activated ester. 
Optimisation of yield is extremely important for GC 1 and its analogues due to the 
presence, near the N-terminal end of the peptide, of an Asp-Gly pair. Such pairs of 
residues are prone, under both acidic and basic conditions to undergo a cyclisation to 
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Fig. 2.16. Acid & base catalysed aspartimide formation 
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The aspartimide can then be opened by nucleophilic attack to give either the required 














Fig. 2.17. Nucleophilic attack on an aspartimide to give a- and -peptides 
Analytical HPLC of crude, cleaved GC  and its analogues, KU 17 and KU 18, clearly 
shows that a significant proportion of the peptide has undergone aspartimide 
formation. The required peptide and the aspartimide-containing product elute very 
close together, thus making preparative HPLC very difficult and resulting in loss of 
yield. Clearly, then, if two chemical steps and concomitant losses in yield could be 
avoided, this would be advantageous. 
The analogues, KU17 and KU18, have been tested for cross-reactivity with the 
polyclonal antibodies raised against GC1 by Graham Cotton. The peptides, GC1, 
KU 17 and KUI 8, were bound to plates and treated with varying dilutions of anti-
GC1 serum. After washing, this was treated with a goat anti-mouse Ig(G,A,M)-
horseradish peroxidase complex. Finally, treatment with tetramethylbenzidine in the 
presence of hydrogen peroxide resulted in a coloured solution, the optical density of 
which indicates the extent of anti-GC 1 binding to the peptide"'. 
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Interestingly, as can be seen from figure 2.18, the analogues have been shown to 
cross-react to a similar extent to GC 1 itself. This suggests that KU 17 and KU 18 are 
at least capable of adopting the same conformations as GC I, though whether their 
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Fig. 2.18. Comparison of the cross-reactivities of GC1 and analogues with anti- 
GC1 antibodies 
2.7. NMR 
3D NMR studies were carried out on the '3-turn'-containing peptides, those 
containing the CysProD.ValCys sequence, KU2 and KU 17, and those containing the 
ACPC residue, KU3 and KU1 8. It was hoped that some n-sheet structure would be 
apparent. Whilst the DQ COSY and TOCSY spectra showed some dispersion, there 
was no evidence for NOESY cross peaks relating to residues other than those 
adjacent to one another, showing that these peptides do not adopt a well-defined 
structure in solution. Although this is somewhat disappointing, the peptides should 
nevertheless be capable of adopting the required 13-sheet structure under the influence 
of an external agent, e.g., in the case of KU 17 and KU 18, binding to an antibody. 
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2.8. 3-Aminocyclopentane-1-carboxylic Acid as a 3-turn Mimic 
The NMR data do not give any direct evidence of ACPC behaving as a 13-turn mimic. 
However, peptides in which the 13-turn formed by the dipeptide sequence ProD.Val is 
held in its conformation by a disulphide bond give similar NMR spectra to their 
ACPC analogues. Therefore the lack of NMR evidence for 13-sheet structure cannot 
be taken as proof that ACPC is not, or is not capable of, acting as a 13-turn mimic. 
The circular dichroism (CD) spectra of the GC  analogues, KU 17 and KU 18, are 
very similar (Fig. 2.19), indicating that they adopt similar solution-phase 
conformations, suggestive evidence for ACPC as a 13-turn mimic. 
KU17 Boric Acid 0.375mg/mi 0.02cm 
KU17 50% TFE 0.375mg/mi 0.02cm 
KU18 Boric Acid 0.65 mg/mi 0.02cm 
- 	KU18 50% TFE 0.65 mg/mi 0.02cm 
Fig. 2.19. CD spectra of KU17 and KU18 
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It is to be expected, with a flexible n-turn mimic such as ACPC, that the degree to 
which it promotes turn formation is dependent upon the peptide sequence. This is 
clearly seen with a sequence from nerve growth factor (NGF) which was synthesised 
by Angela Kelly (AK20)97. The solution structure has been elucidated by NMR'°7. 
Thus it has been shown that the peptide does not adopt the predicted n-sheet 
structure, but rather the ACPC moiety appears to act as a hydrophobic core with the 
peptide backbone being wrapped around it. 
In conclusion, it cannot be positively said that ACPC acts a n-turn mimic; however, 
it may do so where the surrounding peptide sequence has a propensity to form a 13-
sheet structure. 
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KU! 	proIL-1 p 113-122 CysGlyGlyCys 160-163 
YVHDAPVRSLCGGCMSFV 
KU2 	proIL-1 p 113-122 CysProDValCys 160-163 
YVHDAPVRSLCPdVCMSFV 
KU3 	prolL-1 3 113-122 (ACPC) 160-163 
YVHDAPVRSL(ACPC)MSFV 
KU4 proIL-1 113-120 
YVHDAPVR 
KU5 	proIL-1 111-122 "6Glu 
EAYVHEAPVRSL 




Ac LVADCAST NH2 
KU8 	CrmA 300-307 304A1a305Cys 
Ac LVADACST NH2 
KU9 	CrmA 298-309 
Ac CAL VADCASTVT NH2 
KU1O CrmA297-309 
Ac TCALVADCASTVT NH2 
KU!1 proICE89-119 
LSADQTSGNYLNMQDSQGVLSSFPAPQAVQD 
KU12 prolCE 66-88 
AQACQICITYICEEDSYLAGTLG NHNH2 
KU13 LIFAG NHNH2 
KU14 prolCE 1-119 
KU15 proIL-1 111-116 
EAYVHD 
KU16 proIL-1 117-122 
APVRSL 
KU17 HIVIJIB gpl20 Lys 364-378 ProD.Val 445-459 
KSSGGDPEIVTHSFNCPdVCSSNITGLLLTRDGG 




All Fmoc-amino acids were purchased from Novabiochem, Bachem or Raylo, with 
the exception of Fmoc-cis-3-aminocyclopentane-1-carboxylic acid (FmocACPC), 
FmocCys(Phenac) and FmocCys(MeOPhenac), which were prepared in this 
laboratory by the methods described in this text, or of A Brown"'. Optically pure 
cis-3-aminocyclopent-4-ene-1-carboxylic acid was obtained from Chiroscience. All 
amino acids are of the L-configuration, unless otherwise stated. Peptide synthesis 
grade trifluoroacetic acid (TFA) was obtained from Applied Biosystems. Peptide 
synthesis grade dimethylformamide (DMF) and 1 ,4-dioxan, and HPLC grade 
acetonitrile, were obtained from Rathburn Chemicals. Automated peptide syntheses 
were carried out on an ABI 430A peptide synthesiser. LTV spectra were recorded on 
a Varian Cary 210 double beam spectrophotometer. Sonication was carried out in a 
Decon FS300b sonic bath. NMR spectra were recorded on Brucker WP200 
(200MHz), Brucker WH-360 (360MHz) and Varian VXR5 000 (600MHz) 
instruments; chemical shifts were measured relative to TMS assigned to zero. Fast 
atom bombardment mass spectra (FAB MS) were measured on a Kratos MS50TC 
machine, electron ionisation mass spectra (El MS) on a Kratos 902MS, and time of 
flight (TOF MS) on a Perspective Biosystems LaserTec Benchtop II laser desorption 
system from Vestec mass spectrometry products. Circular dichroism spectra were 
recorded in Stirling on a JASCO J600 spectropolarimeter. Fluorescence spectra were 
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recorded on a Perkin-Elmer LS50 luminescence spectrometer fitted with a Grant 
LTD-6 thermostatic control. Infrared spectra were recorded on a BlO-RAD 
SPC3200 instrument. Optical rotations were measured using an AA1000 polarimeter 
(Optical Activity Ltd). Elemental analyses were performed on a Perkin-Elmer 2400 
CHN elemental analyzer. Melting points were recorded in open capilliaries on a 
Buchi 510 oil immersion melting point apparatus, and are uncorrected. Throughout 
the text, ether refers to diethyl ether and dioxan to 1 ,4-dioxan. 
3.2. Solid Phase Peptide Synthesis 
3.2.1. Side-chain Protecting Groups in Fmoc SPPS 
The following amino acids are coupled without side-chain protection: 
Ala, Gly, Ile, Leu, Met, Phe, Pro, Trp, Val. 
The following are coupled with side-chains protected as 'Bu esters: 
Asp, Glu. 
The following are coupled with side-chains protected as 'Bu ethers: 
Ser, Thr, Tyr. 
Arg is protected by the pentamethylchromansulphonyl (Pmc) group, His by the trityl 
(Trt) group and Lys as a urethane by the t-butyloxycarbonyl (Boc) group. 
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The remaining residues, Cys, Asn and Gin, may be coupled in a variety of forms, the 
choice of protecting group being dependent on the sequence and/or synthetic 
strategy. 	Cys is commercially available as Cys(Trt), Cys(S'Bu) and Cys- 
acetamidomethyl (Acm) derivatives. The trityl group is removed under standard 
TFA cleavage conditions, whilst the other two groups are stable to TFA and are 
removed subsequently under specialized conditions. Two other TFA stable Cys 
protecting groups have been used in this work, phenylacetamidomethyl (Phenac) and 
4-methoxyphenylacetamidomethyl (MeOPhenac), the Cys derivatives being prepared 
in this laboratory. Asn and Gin may be coupled with no side-chain protection, or 
may be protected by Trt or 4,4'-dimethoxybenzhydryl (Mbh) groups. In the case of 
these variable amino acids, the protecting group used in each synthesis is specified in 
the text. 
3.2.2. Loading Wang Resin for Peptide-acid Synthesis 
The first amino acid residue is coupled to the resin via its symmetrical anhydride. 
Fmoc-amino acid (6 equivalents) and DIC (3 equivalents) are stirred in DMF (5ml) 
for 15 minutes. Wang resin and a catalytic amount of DMAP (approximately 8mg) 
are added. Extra DMF may be added if required, to fully swell the resin. The 
mixture is sonicated for two hours at room temperature. The resin is separated by 
filtration and washed with copious DMF, dioxan and DMF. Finally the resin is dried 
by washing with ether. 
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If a low resin loading is required the procedure may be modified as follows; 1.5 
equivalents of the symmetrical anhydride may be used (hence 3 equivalents of Fmoc-
amino acid and 1.5 equivalents of DIC), and the mixture may be sonicated for just 
one hour. 
When synthesising peptide-amides, manual loading of the first amino acid is 
unnecessary; the whole chain assembly may be carried out automatically. 
3.2.3. The Fmoc Loading Test 
Dry Fmoc-amino acid resin (2-3mg), accurately weighed, is sonicated in 20% 
piperidine/DMF (lOmi) for 10 minutes. The resin is removed by filtration and the 
UV spectrum of the filtrate recorded between 340 and 280nm. The percentage 
loading is calculated from the absorbance of the piperidine-Fmoc adduct at 302nm, 
by a computer program using the Beer-Lambert law, calibrated against known 
quantities of Fmoc-Gly-OH. The average of two such tests determines the resin 
loading. 
3.2.4. Automated Peptide Synthesis 
A single cycle of an automated synthesis, resulting in the coupling of a single 
residue, comprises the following steps: 1. capping, to block any unreacted free 
amines, which would result in the synthesis of a peptide missing one of its internal 
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residues; 2. deprotection, to remove the N-u, protecting group (Fmoc) in preparation 
for the coupling of the next amino acid; 3. coupling, either once, twice or, 
exceptionally, three times (Fig 3.1). 
Capping 
The resin is shaken with 0.5M acetic anhydride, 0.125M DIEA and 0.2% HOBt in 
DMF (lOml) for 10 minutes. The capping solution is then drained from the reaction 
vessel and the resin washed with 6 portions of DMF. 
Deprotection 
The resin is shaken with 20% piperidine/DMF (lOmi) for 3 minutes. It is drained, 
washed four times with DMF, and then shaken with further 20% piperidine/DMF 
(lOmi) for 1 minute. Finally the resin is washed with 6 portions of DMF/dioxan 
(1:1). 
The percentage of amino acid successfully coupled in the preceding cycle is 
determined by analysis of an aliquot of the deprotection filtrate. The UV absorbance 
of the sample at 302nm is measured by an ABI 758A detector, with on-line 
integration. Comparison of the area of each successive deprotection peak with that 
of the first amino acid allows an estimate of the percentage coupling of each residue 
to be made. 
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Fmoc 	AA1  LINKER/-D 
+ some AA, LINKER( 
Cap Ac20, DIEA, HOBt 
FmocAA 2 AAlLINKER® 
Ac AA LINKER( 




AA 2 AA LINKER® 
Ac AA LINKER( 
Couple I Symmetrical Anhydrid 
Fmoc AA  
'2  AA1 LINKER® 
'2 AA  LINKER® 
Ac 
Couple II HOBt Activated Ester 
Fmoc AA 3AA2AAl
O 
<<1%! AA2  AA i LINKER® 
Ac AA LINKER 
last time 
Fmoc AAn ....... 
etc 
Fig. 3.1. Schematic showing the key stages in an automated double couple cycle. 
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3. Coupling 
The standard double couple cycle used for most syntheses consists of one coupling 
using 2 equivalents of symmetrical anhydride, followed by a second with 2 
equivalents of HOBt activated ester. The exceptions to this are asparagine, 
glutamine and histidine, which are coupled twice as the HOBt activated ester (never 
the symmetrical anhydride), and glycine, which is single coupled using 4 equivalents 
of the symmetrical anhydride. In the synthesis of large peptides (>50 residues) this 
procedure is modified, the second coupling being carried out with 4 equivalents of 
activated ester. When, exceptionally, a residue is coupled three times, a symmetrical 
anhydride coupling is followed by two HOBt activated ester couplings (for the 
standard residues). 
Both the symmetrical anhydride and the activated ester are preformed in an 
'activation vessel' before being transferred to the reaction vessel. For symmetrical 
anhydride formation, immol of Fmoc-amino acid is treated with 0.5mmol of DIC in 
DMF/dioxan (1:1, 8m1) for 10 minutes, whilst the activated ester is formed by the 
reaction of O.Smmol Fmoc-amino acid, 0.5mmol HOBt and O.Smmol DIC, also in 
DMF/dioxan (1:1, 8ml) for 20 minutes. In both cases coupling is allowed to proceed 
for 30 minutes in a standard cycle. When extended coupling times are used the SA is 
coupled for 1 hour and the AE for 1.5 hours. 
The resin is washed four times. 
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4. The end cycle 
Once chain assembly is complete another capping step is carried out. The final Fmoc 
group may be left on the peptide and removed manually later. Alternatively the 
Fmoc may be removed by a final deprotection step. The peptide may be left with a 
free N-terminal amine, or, if an acetylated peptide is required, a further capping step 
may be carried out. 
3.2.5. Manual Peptide Synthesis 
The procedure for manual peptide synthesis using bubbler apparatus (see Fig 3.2) is 
essentially the same as described above for automated synthesis. Activation of the 
amino acids is carried out in a separate round-bottomed flask. A single, 10 minute, 
deprotection step is used. 
Monitoring of the coupling efficiency by UV is not carried out. Instead it is possible 
to ascertain whether complete coupling has taken place by carrying out a Kaiser test. 
Kaiser Test 
A few beads of damp resin are placed in a small vial. 76% w/w phenol/ethanol 
(75j.il), 0.2mM potassium cyanide/pyridine (100p!) and 0.28M ninhydrinlethanol 
(75p1) are added. The vial is placed in a heating block at >100°C for 7 minutes. If 
81 
free amine groups are present the solution and beads will show a blue tinge. 
However if the coupling is complete the solution will remain yellow and the 
synthesis may continue. 
-*- pump 
Fig. 3.2. Bubbler Apparatus for the Manual Synthesis of Peptides. 
The peptide-resin is contained within the cylindrical reaction vessel, and is agitated 
with nitrogen. Reagents are added manually from the top and removed under suction 
through the glass sinter at the bottom of the reaction vessel. Waste solvents and 
excess reagents are collected in the lower reservoir. 
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3.2.6. Loading TbFmoc onto Peptide-resin 
The loading of the last amino acid residue in the peptide chain is ascertained 
accurately by carrying out an Fmoc loading test (see section 3.2.2). Between 3 and 
10 equivalents of TbFmoc chloroformate are dissolved in DCM (5ml). The resin is 
added, followed by an amount of DIEA equivalent to that of the TbFmocCl used. 
The mixture is sonicated in the dark for three hours. The resin is filtered and washed 
with DCM, then returned to the flask with fresh DCM and sonicated for a further 10 
minutes. This procedure is repeated to ensure that all excess TbFmocCl is removed. 
The resin is dried by washing with ether; it is stored in dioxan at 4°C, in the dark. 
All further manipulations of TbFmoc-peptides (cleavage, lyophilisation etc) must be 
performed in the dark. 
3.2.7. The TbFmoc Loading Test 
Dry TbFmoc-peptide-resin (1-3mg), accurately weighed, is sonicated in 20% 
piperidine/dioxan (2m1) for 10 minutes. The UV spectrum of the solution is recorded 
between 400 and 340nm. The percentage loading is calculated from the equation: 
% loading = 0.613 x Absorbance at 364 nm x 100 
5 x weight of resin in mg 
The average of two such tests determines the TbFmoc loading. 
83 
3.2.8. Acidolytic Cleavage from the Resin 
Peptide-amides and peptide-acids are both cleaved and deprotected under the same 
conditions. Two methods are used, aqueous TFA cleavage and the anhydrous 
trimethylsilyl bromide (TMSBr) cleavage. In both cases it is necessary to include 
cation scavengers in the reaction mixture to prevent the attack of sensitive residues 
by the dislodged protecting groups. 
Aqueous TFA Cleavage 
The dry peptide-resin is placed in a small round-bottomed flask containing a 
magnetic stirrer bar and fitted with a nitrogen bubbler. The scavengers are added to 
the resin and the mixture is stirred for 10-15 minutes. (The choice of scavengers 
depends on the residues present; the scavengers which have been used during this 
work are specified in the text.) Water and TFA are added and the mixture is stirred 
under nitrogen at room temperature for a variable length of time, dependent upon the 
length of the peptide and the nature of the protecting groups. 
Anhydrous TMSBr Cleavage 
TFA (7.5ml), m-cresol (lOOpi), EDT (500pi) and thioanisole (1.l7ml) are placed in a 
round-bottomed flask and cooled on ice for 30 minutes. TMSBr (1.3m1) is added and 
the mixture cooled for a further 5 minutes before the addition of the dry peptide- 
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resin. The mixture is stirred, with cooling on ice, under a slow stream of nitrogen, 
for a time dependent upon the nature of the peptide. 
Work-up 
The work-up is carried out in the same way for both cleavage methods. The resin is 
removed by filtration and washed with TFA. The volume of TFA is reduced in 
vacuo and the peptide triturated from the resultant dark oil by the addition of ether. 
The peptide is filtered on a glass sinter and washed with further ether. Finally it is 
dissolved from the sinter in aqueous acetic acid (usually 20% AcOI-I/H20), and 
lyophilised to give the crude peptide. 
3.2.9. High Performance Liquid Chromatography 
Reverse phase HPLC for the analysis and purification of cleaved peptides is carried 
out using an ABI 1783A programmable detector, two ABI 140A solvent delivery 
pumps and an ABI 1408A injector. The columns referred to in the text are: 
Analytical Columns 
ABI Aquapore RP300 reverse phase silica (300A pore size, 7tm spherical silica) 
220 x4.6mm C18 
100 x4.6mm C18 
220 x 4.6mm C8 
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Vydac reverse phase silica (300A pore size, 5tm spherical silica) 
250 x 4.6mm C18 
250x4.6mmC8 
Preparative Columns 
ABI Aquapore RP300 (equivalent to analytical columns) 
110x9.2mmC18 
250 x 9.2mm C18 
110x9.2mmC8 
250 x 9.2mm C8 
Vydac reverse phase silica (1 Ojim particle size) 
250 x22mm C18 
The peptides are eluted by an increasing concentration of acetonitrile in water. The 
solvent system used is: 
Solvent A: 	H20/0-  I% TFA 
Solvent B: CH3CN/0.l% TFA 
In this work, two gradients were used for analytical HPLC: 
gradient I: (t,%B) (0,10)(30,90)(32,10) 
gradient II: (t,%B) (0,1 0)(2, 1 0)(32,90)(34,90)(36, 10) 
For preparative HPLC the gradient used was dependent on the nature and quantity of 
impurities present. The conditions used are specified in the relevant part of the text. 
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3.2.10. Amino Acid Analysis 
Approximately 1mg of peptide is dissolved in approximately 2m1 of 6M HC1 in a 
Carius tube. The sample is degassed and the tube is sealed. Hydrolysis is carried out 
at 110°C for 24 hours. For large peptides (>50 residues) hydrolysis proceeds for 48 
hours. The aqueous HC1 is then removed in vacuo, and the hydrolysed material 
redissolved in sodium citrate buffer, pH2.2 (2m1) for analysis. This is carried out on 
an LKB 4151 amino acid analyser. 
3.2.11. The Ellman's Test 
The Ellman's test is used to reveal the presence or absence of free thiols. It may be 
performed either quantitatively, or qualitatively, when a bright yellow solution 
resulting from the production of the nitrothiobenzoate (NTB) chromophore indicates 
the presence of unprotected cysteines. 
02N___S_S__ I__NO2 
-o2c 	 c02- 
+ 
R - S - s__Q__ NO, 
Co2. 
+ 
R - - 	
-s 	 NO2 
NTB CO2- 
Fig. 3.3 The Ellman's Test 
0.1-0.2mg of peptide are dissolved in 6M guanidine HCI with 0.1M phosphate buffer 
(pH7.3) and 1mM EDTA (2ml). 100il of a 3mM solution of 5,5'-dithiobis(2- 
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nitrobenzoic acid) (DTNB) in O.1M phosphate buffer (pH7.3) is added, and the 
solutions thoroughly mixed by shaking. Colour development is rapid. 
For a quantitative test the absorbance of the protein solution is measured at 412nm. 
Knowing that the extinction coefficient of the NTB anion in 6M guanidine HCl is 
13700/M cm, the molar concentration of free thiols can be calculated. 
3.3. Experimental 
KU2 prolL-1 13113-122-Cys-Pro-D.Val-Cys-160-163 
Tyr Val His Asp Ala Pro Val Arg Ser Leu Cys Pro D.Val Cys Met Ser Phe Val 
The synthesis was carried out on a 0.25mmole scale, starting with FmocVal-resin 




D.Val which were given extended coupling times. Cys was protected with 
S'Bu groups. The final Fmoc group was left on the peptide, but the deprotection 
profile of 
2
Val showed 99% coupling efficiency at this residue (yield peptide-resin 
1.558g). 
Fmoc peptide-resin (470mg) was sonicated in 20% piperidine/DMF (lOmi) for 20 
minutes to remove the Fmoc group, filtered and washed with DMF, 1,4-dioxan and 
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DMF. The peptide was deprotected and cleaved from the resin by stirring in TFA 
(lOmi) with water (imi), anisole (500p1), thioanisole (600 jtl) and EDT (200.tl) under 
nitrogen for 2.5 hours. The crude peptide (152mg) was purified by preparative 
HPLC (column G; 5m1/min; (t,%B) (0,10)(10,40)(35,80)(36,90)(38,90)(40,10)) and 
lyophilised to give S
t 
 Bu protected peptide (40mg). 
For removal of the cysteine protection, peptide (40mg) was dissolved in 
5%water/TFE (20m1) and tributyiphosphine (50t1) was added. The reaction was 
followed by analytical HPLC (column A) and after 2.5 hours most of the solvent was 
removed in vacuo. The peptide was precipitated by the addition of ether, filtered and 
washed with further ether. 
Air oxidation was carried out immediately. The peptide was dissolved in tris buffer 
(0.1M, 400m1, pH8) and stirred vigorously for 42 hours. Once again, the reaction 
was followed by analytical HPLC (column A). The solution was lyophilised in two 
portions. The peptide was then separated from the salt by preparative HPLC (column 
G; 5m1/min; gradient (t,%B) (0,10)(5,30)(17,45)(19,90)(21,10)). An Eliman's test of 
the lyophilised material showed that it contained no free thiols. 
FAB MS: MH 2022.0 (for C90H137N23024S3 expect 2022.4); 
HPLC: (column D; gradient I; loop 100 j.il) Rt  14.2 mm; 
AAA: Asp1 1.01, Ser2 1.56, Pr02 1.46, Ala1 1.10, Cys2 1.89, Va14 3.82, Met1 1.09, 
Leu1 1.16, Tyr1 0.89, Phe1 0.99, His1 0.93, Arg1 1.19 
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CD: 	 a-helix 	 n-sheet 	random coil 
50mM sodium borate 
buffer 	 0% 	 54% 	 46% 
50% TFE/sodium 
borate buffer 	 0% 	 46% 	 54% 
(+)-cis-aminocyclopentane-1 -carboxylic acid 
(+)-cis-aminocyclopent-4-ene-1-carboxylic acid (499.6mg, 3.97mmol) was dissolved 
in methanol (70m1) and Pd/C, (50mg) was added. The mixture was stirred under 
hydrogen overnight. 
The Pd/C was removed by filtration through celite and the methanol removed in 
vacuo to give the title compound as a white solid (yield 5 04.4mg, 98.5%). 
mp: 200°C (dec); El MS: MH 129 (for C6H,,NO2 expect 130); (found: C, 55.03; H, 
8.84; N, 10.61, caic. for C6H11NO2: C, 55.81; H, 8.53; N, 10.85%); FT JR 
(bromoform mull): v 3018, 1640, 1542, 1400cm 1 ; 'H NMR (DMSO-d6/TFA-d, 
200MHz): 3.67, m, 111; 2.81, m, 1H; 1.98-1.55, complex, 6H; [a]23589: +10.0° (c, 1 in 
MeOH); Rf (CHC13:MeOH:AcOH, 85:10:5): 0 (baseline); Rf  
(nlBuOH:py:H20:AcOH, 15:10:12:3): 0.31. 
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(+)-N-(9-fluorenytmethoxycarbonyl)-cis-3-aminocyclopentane-1 -carboxylic acid 
(+)-Cis-3 -aminocyclopentane- 1 -carboxylic acid (473mg, 3 .67mmol) was suspended 
in water (lOmi) and dioxan (20m1). Triethylamine (767pi, 5.5mmol, 1.5 equivalents) 
and 9-fluorenylmethyl succinimidyl carbonate (1.11 2g, 3 .3mmol, 0.9 equivalents) 
were added and the resulting mixture was stirred at room temperature overnight. 
The reaction mixture was diluted with water (1 OOml) and cooled on ice before being 
acidified to pHi .5 by the addition of 2M HC1. It was extracted with ethyl acetate 
(2x130m1), and the combined organic fractions were washed with water (120m1) and 
brine (120m1) before being dried over MgSO4. 
The drying agent was removed by filtration, and the solvent was removed in vacuo to 
give the crude product. This was recrystallised from ethyl acetate/hexane to give the 
title compound as a white solid (yield 831.6mg, 71.8%). 
mp: 166-167.5°C; FAB MS: MH 352.15522 (for C21H22N04 expect 352.15488); 
(found: C, 71.86; H, 6.40; N, 3.82, calc. for C21H22N04: C, 71.79, H, 5.98, N, 3.99); 
FT JR (bromoform mull): v 3298, 3251, 3018, 1711, 1645, 1425cm
1
; 'H NMR 
(CDC13, 360MHz): 7.76-7.28, in, 81-1; 4.46-4.11, in, 4H; 2.9, in, 1H; 2.26-1.69, 
complex, 61-1; '3C NMR (CDC13, 90MHz): 181.912 (CO21-1), 155.732 (urethane), 
143.808, 141.195 (Fmoc Ar quarternary), 127.551,126.913, 124.950, 119.835 (Fmoc 
Ar CH), 66.544 (Fmoc CH2), 52.479 (CH adjacent to NH), 47.120 (Fmoc CH), 
41.559 (CH adjacent to CO2H), 39.952, 32.982, 27.932 (CH2); [a]23589: +13.0° (c, 1 
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in MeOH); Rf (CHC13:MeOH:AcOH, 85:10:5): 0.52; Rf (nBuOH:py:H20:AcOH, 
15:10:12:3): 0.75. 
KU3 prolL-1 1 13-122-13-turn-mimic-160-1 63 
Tyr Val His Asp Ala Pro Val Arg Ser Leu ACPC Met Ser Phe Val 
The synthesis was carried out on a 0.25 mmole scale, starting with FmocVal-resin 
10 	14 
(0.6mmol/g, 420mg). The first 5 residues, Leu- Phe, were coupled manually using 
bubbler apparatus. A Kaiser test was performed after each coupling, and the 
synthesis did not proceed to the next residue until no blue coloration was seen. The 
coupling methods and times were as follows: Phe, symmetrical anhydride (SA), 2 
equivalents, 1 hour & HOBt activated ester (AE), 2 equivalents, 1.5 hours; Ser, SA, 
2 equivalents, 1 hour; Met, SA, 2 equivalents, 1 hour & HOBt AE, 2 equivalents, 1.5 
hours; ACPC, HOCt AE, 4 equivalents, overnight; Leu SA, 2 equivalents, 1 hour & 
HOBt AE, 2 equivalents, 2.25 and 1.25 hours. The synthesis was completed using 
automated double couple cycles. The overall coupling efficiency of the synthesis 
could not be ascertained due to the presence of an air bubble in the flow cell of the 
monitoring system (yield peptide-resin 843mg). 
Deprotection and cleavage from the resin were carried out by stirring resin (400mg) 
in TFA (12m1) with water (2ml) and EDT (200.x1) under nitrogen for 3 hours. The 
crude peptide (172mg) was purified by preparative HPLC (column G; 5m1/min; 
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gradient (t,%B) (0,10)(5,10)(30,50)(32,10)) and lyophilised to give the title 
compound (8 8mg). 
FAB MS: MH 1733.5 (for C80H122N20021S expect 1733); 
HPLC: (column A; gradient II; loop 2m1) R 14mins; 
AAA: Asp1 0.98, Ser2 1.71, Pro1 1.58, Ala1 1.12, Va13 3.14, Met1 1.06, Leu1 1.08, 
Tyr1 1.07, Phe1 0.83, His1 1.02, Arg1 1.10. 
KU4 prolL-113 113-120 
Tyr Val His Asp Ala Pro Val Arg 
The synthesis was carried out on a 0.25 mmole scale, starting with FmocArg(Pmc)-
resin (0.59mmol/g, 425mg), standard double couple cycles being used throughout. 
The coupling efficiency for the final residue was 91.5% (yield peptide-resin 609mg). 
Deprotection and cleavage were carried out by stirring peptide-resin (122mg) in TFA 
(5m1) with water (0.5m1) and anisole (0.25m1) under nitrogen for 3 hours. Crude 
peptide (4 1mg) was purified by preparative HPLC (column G; 5m1/min; gradient 
(t,%B) (0,10)(15,50)(17,10)) to give the title compound on lyophilisation (yield 
21.6mg). 
FAB MS: MH 957 (for C43H65N13012 expect 957.1); 
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HPLC: (column C; gradient I; loop 2m1) Rt 5mm; 
AAA: Asp1 1.02, Pro1 1.01, Ala1 1.12, Va12 1.98, Tyr1 0.96, His1 0.94, Arg1 0.97 
KU5 proIL-1fE 111-122 116Glu 
Gin Ala Tyr Val His Glu Ala Pro Val Arg Ser Len 
The synthesis was carried out on a 0.25mmole scale, starting with FmocLeu-resin 
(0.62mmol/g, 400mg) and using standard double couple cycles throughout. The 
overall coupling efficiency was 45% (yield peptide-resin 772mg). 
Deprotection and cleavage were carried out by stirring peptide-resin (300mg) in TFA 
(lOml) with water (1.5m1) and anisole (0.5m1) for 3 hours. The crude peptide 
(130mg) was purified by preparative HPLC (column G; 5m1/min; gradient (t,%B) 
(0, 10)(10,50)(12,10)) to give the title compound (yield 105mg). 
FAB MS: MH 1370.6 (for C61H95N17019 expect 1371.6) 
HPLC: (column A; gradient I; loop 2m1) Rt 9.2mm 
AAA: Ser1 0.92, G1u2 2.33, Pro1 1.03, Ala2 2.25, Va12 1.81, Leu1 1.06, Tyr1 0.99, 
His1 0.95, Arg1 1.01. 
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119 KU6 prolL-113 111-122 D.Val 
Glu Ala Tyr Val His Asp Ala Pro D.Val Arg Ser Leu 
The synthesis was carried out on a 0.1 9mmole scale, starting with FmocLeu-resin 
(0.62mmol/g, 3 00mg). Double couple cycles were used throughout with 'Glu to 5His 
being given extended coupling times. The overall coupling efficiency was 90% 
(yield peptide-resin 646mg). 
Deprotection and cleavage were carried out by stirring peptide-resin (296mg) in TFA 
(lOmi) with water (1.5ml) and anisole (0.5m1) for 3 hours. The crude peptide 
(121mg) was purified by preparative HPLC (column G; 5m1/min; gradient (t,%B) 
(0,10)(15,50)(17,10)) to give the title compound (yield 90mg). 
FAB MS: MH 1356.4 (for C60H93N17019 expect 1357.5); 
HPLC: (column A; gradient I; loop 2m1) Rt 9.8mm; 
AAA: Asp1 1.03, Ser, 0.89, G1u1 1.16, Pro1 1.15, Ala2 2.10, Va12 1.76, Leu, 1.02, 
Tyr, 0.94, His1 0.91, Arg, 1.12. 
KU7 CrmA 300-307 
Ac Leu Val Ala Asp Cys Ala Ser Thr NH2 
The synthesis was carried out on a 0.25mmole scale using Fmoc-amide resin 
(0.32mmo/g, 780mg). Standard double couple cycles were used throughout and the 
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cysteine was protected with a trityl group. The overall coupling efficiency of the 
synthesis was not ascertained due to the presence of an air bubble in the flow cell of 
the monitoring system. However, amino acid analysis of the crude, cleaved peptide 
indicated that approximately 50% was the required peptide. (Yield peptide-resin 
1.097g). 
Deprotection and cleavage were carried out by stirring peptide-resin (420mg) in TFA 
(lOml) with water (500tl), anisole (400tl) and EDT (100tl) under nitrogen for 
1.5hours. The work-up was carried out using ether containing DTT (2%) and 
lyophilisation from 50mM ammonium acetate containing DTT (5%) gave the crude 
peptide (yield 142mg). The peptide was dissolved in aqueous 6M guanidine 
hydrochloride brought to a pH of approximately 9 by the addition of tris base, and 
containing DTT (2%) for preparative HPLC (column K; 9m1/min; gradient (t,%B) 
(0,10)(10,10)(55,90)(57,10)). Two major fractions were collected, of which the first 
was the title compound (yield 29.8mg). 
FAB MS: MH 820 (for C33H57N9013S1 expect 820.9; 
HPLC: (column B; gradient I; loop 2m1) Rt 7mm; 
AAA: Asp1 1.01, Thr1 0.97, Ser1 0.91, Ala2 2.12, Cys1 0.63, Va11 1.05, Leu1 0.99. 
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,- KU8 CrmA 300-307 304  Ala 305  ys 
Ac Leu Val Ala Asp Ala Cys Ser Thr NH2 
The synthesis was carried out on a 0.25mmole scale using Fmoc-amide-resin 
(0.32mmol/g, 780mg). The cysteine was protected with a trityl group. 6Cys-8Tbr 
were coupled using standard double couple cycles. The remaining residues were all 
given extended coupling times with 'Leu and 5Ala being triple coupled (1xSA, 
2xHOBt AE). The synthesis was interrupted before the final Fmoc deprotection and 
a small amount of resin removed so that the coupling efficiency could be checked 
manually (see 3.2.2). This showed an overall coupling efficiency of just 57%. 
Therefore the leucine was recoupled using the HOCt activated ester (no improvement 
in coupling efficiency was seen). Finally the leucine was recoupled using 4 
equivalents of the HOBt activated ester with overnight sonication. This resulted in a 
final coupling efficiency of >90% (yield peptide-resin 1.068g). 
Deprotection and cleavage were carried out by stirring peptide-resin (350mg) in TFA 
(lOml) with water (0.5m1), anisole (0.5m1) and EDT (100d) under nitrogen for 2 
hours (yield crude peptide 134mg). Work-up and preparative HPLC were as for 
KU7, giving two major fractions, of which the earlier eluting gave the title compound 
on lyophilisation (yield 11 mg). 
FAB MS: MH 820 (for C33H57N9013S1 expect 820.9); 
HPLC: (column A; gradient I; loop 2m1) Rt 11.4 mm; 
AAA: Asp1 1.10, Ser1 0.87, Thr1 0.96, Ala2 2.21, Cys1 0.54, Va!1 1.05, Leu1 1.00. 
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KU9 CrmA 298-309 
Ac Cys Ala Leu Val Ala Asp Cys Ala Ser Thr Vat Thr NH2 
The synthesis was carried out on a 0.25mmole scale, starting with Fmoc-amide-resin 
(0.32mmol/g, 780mg). Double couple cycles were used throughout, 3Leu to 6Asp 
being given extended coupling times. The cysteines were protected with Acm 
groups. The overall coupling efficiency was 87% (yield peptide-resin 1.239g). 
Deprotection and cleavage were carried out by stirring peptide-resin (496mg) in TFA 
(lOmi) with water (0.5m1) and anisole (0.5m1) under nitrogen for 2 hours 20 minutes. 
The crude peptide (197mg) was dissolved in basicified aqueous guanidine 
hydrochloride and purified by preparative I-IPLC (column K; 9ml/min; gradient (t, 
%B) 	(0,1 0)( 10,1 0)( 1 5,40)(3 5,50)(45,90)(47, 10)). 	Lyophilisation gave the Acm 
protected peptide (139mg). 
FAB MS: MH 1336 (for C54H93N15020S2 expect 1337.6); 
HPLC: (column D; gradient I; loop 5m1) Rt 15.7mm. 
Removal of the Acm protecting groups was carried out using silylated glassware. 
Peptide (15mg) and silver trifluoromethanesuiphonate (silver triflate) (20 
equivalents, 0.224mmol, 58mg) were cooled on ice, and TFA (5m1) was added. The 
mixture was stirred in the dark with cooling on ice for 3 hours, after which most of 
the TFA was removed in vacuo. Care was taken to avoid taking the flask to dryness. 
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DTT (100 equivalents, 1.12mmol, 170mg) in tris buffer (0.1M, pH8, 5m!) was added 
to the flask and stirred in the dark, overnight, at room temperature. The suspension 
was transferred to a centrifuge tube and centrifuged at 4500rpm for 30 minutes. The 
supernatant was removed, the pellet resuspended in basicified aqueous 6M guanidine 
HCl and recentrifuged. The combined supernatants were purified by preparative 
HPLC (column F; 5m1/min; gradient (t,%B) (0,10)(25,35)(27,10)). Lyophilisation 
gave the title compound (yield 7.2mg) as a fluffy white solid giving a positive result 
in the E!lman's test. 
FAB MS: MH 1195 (for C48H83N13018S2 expect 1195.4); 
HPLC: (column C; gradient I; loop 2ml) Rt 13.9 mins; 
AAA: Asp1 1.25, Thr2 1.88, Ser1 0.86, Ala3 3.07, Cys2 0.37, Va12 2.01, Leu1 1.01. 
Cyclisation was carried out by air oxidation. Peptide (10mg) was dissolved in 
aqueous ammonium acetate (50mM, pH9, 1 OOml) and stirred vigorously for 5 days. 
The mixture was lyophilised, redissolved in water and relyophilised to remove most 
of the ammonium acetate, before the last of the salt was removed by preparative 
HPLC (column F; Sml/min; gradient (t,%B) (0,10)(15,40)(17,90)(19,10)). 
Lyophilisation gave the oxidised title compound (yield 3.2mg) as a fluffy, white solid 
giving a negative result in the Ellman's test. 
FAB MS: MH 1192 (for C48H81N13018S2 expect. 1193.4); 
HPLC: (column D; gradient I; loop 2ml) R 13.6mm; 
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AAA: Asp1 1.09, Thr2 1.83, Seri 1.02, Ala3 3.00, Cys2 1.60, Va12 2.00, Leu1 0.98 
KU11 ICE pro region 89-119 
Len Ser Ala Asp Gin Thr Ser Gly Asn Tyr Leu Asn Met Gin Asp Ser Gin Gly 
Val Len Ser Ser Phe Pro Ala Pro Gin Ala Val Gin Asp 
The synthesis was carried out on a 0.25mmole scale, starting with Fmoc-Asp(O'Bu)-
resin (0.664mmo1/g, 377mg). Asn and Gin were coupled without side-chain 
protection. Standard double couple cycles were used throughout and the final Fmoc 
was left on the peptide. The overall coupling efficiency was 50% (yield Fmoc-
peptide-resin 1.292g). 
Fmoc-peptide-resin (130mg) was sonicated in 20% piperidine/DMF (5m1) for 5 
minutes, filtered and washed with DMF, dioxan and ether. Deprotection and 
cleavage were carried out by stirring the peptide-resin in TFA (5ml) with water 
(0.5m1), anisole (200p1) and EDT (lOOpi) under nitrogen for 3 hours. The crude 
peptide (65mg) was purified by preparative HPLC (column J; 5mllmin; gradient 
(t,%B) (0,10)(35,40)(37,90)(39,10)). Lyophilisation gave the title compound (yield 
18.1mg). 
FAB MS: MH 3268.9 (for C138H215N3805251 expect 3270.5); 
I-IPLC: (column A; gradient I; loop 5m1) R1 16.7mm; 
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AAA: Asp5 5.34, Thr1 0.91, Ser5 5.13, G1u5 6.64, Pr02 2.97, G1y2 2.18, Ala3 3.28, 
Va12 2.13, Met1 0.79, Leu3 2.85, Tyr1 1.00, Phe1 1.05. 
Dibenzocycloheptadiene-5-one methoxycarboxy-Ala-PAM Resin 
Boc-Ala-PAM resin (2.86g, 0.56mmolIg, 1 .Smmol) was swollen with DCM (5m1). 
TFA (5m1) was added and the resin was sonicated for 10 minutes. The resin was 
filtered and washed with copious DCM, I 0%DIEAIDMF and DCM. 
2-(Oxyacetic acid)dibenzocycloheptadiene-5-one (846mg, 3mmol) was placed in a 
round-bottomed flask with HOBt (0.25M solution in DMF, 12m1, 3mmol). DIC 
(0.25M solution in dioxan, 12m1, 3mmol) was added and the mixture stirred for 15 
minutes. This was then added to dry Ala-PAM resin and the suspension was stirred 
mechanically overnight. 
The resin was filtered and washed with DMF, methanol, further DMF, and dried with 
ether (yield 2.92g). A quantitative Kaiser test showed that coupling had proceeded 
99.9%. 
FT JR (KBr disc): v 1738, 1685, 1640, 1597cm 1 . 
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Dibenzocycloheptadiene-5-ol methoxycarboxy-Ala-PAM resin 
Dibenzocycloheptadiene-5 -one methoxycarboxy-Ala-PAM resin (2.92g), 
0.51mmol/g, 1.5mmol) was swollen with THF (Na dried, 40m1) and lithium 
borohydride (3 3mg, 1 .5mmole) was added. The mixture was stirred mechanically at 
room temperature for 1 hour. 
The resin was filtered and washed with copious methanol, 0.001M HC1, methanol, 
and dried with ether (yield 2.90g). 
FT JR (KBr disc): v 1740, 1685, 1600cm'. 
N -t- Butyloxycarbonyl -N'- dibenzocycloheptadiene -5- yl methoxycarboxy-Ala-
PAM resin hydrazine (Boc-hydrazide Resin) 
Dibenzocycloheptadiene-5-ol methoxy carboxy-Ala-PAM resin (2.9g) was placed in 
a round-bottomed flask with t-butylcarbazate (1.386g, 10.5mmol). DCM was added, 
followed by benzenesulphonic acid (118mg, 0.75mmol), and the mixture heated at 
reflux, with mechanical stirring, for 6 hours. The resin was filtered and washed with 
copious DCM (yield 2.95g). 
FT JR (KBr disc): v 1740, 1685, 1600cm' 
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FmocGly-hydrazide Resin 
FmocGlyOH (1.458g, 5mmol) was suspended in DCM (lOmi) and oxalyl chloride 
(880j.iI, 1 Ommol) was added, followed by DMF (2 drops). The mixture was stirred 
for 1 hour, until the reaction was complete. The DCM and excess oxalyl chloride 
were removed in vacuo. The residue was redissolved in DCM (10m1) and added to 
Boc-hydrazide resin (500mg), preswollen in DCM (15m1) and pyridine (5m1). The 
mixture was heated under reflux for 4.5 hours. 
The resin was filtered and washed with copious DCM (yield 533mg). An Fmoc 
loading test revealed an Fmoc-Gly loading of 0.25mmol/g. 
KU13 Len lie Phe Ala Gly NHNH2 
The synthesis was carried out on a 0.13mmole scale, starting with Fmoc-Gly-
hydrazide resin (0.25mmol/g, 53 0mg). The synthesis was carried out manually using 
bubbler apparatus; a Kaiser test was performed after each coupling and the synthesis 
did not proceed to the next residue until no blue coloration was seen. Unless 
otherwise stated, each coupling used 4 equivalents of the relevant activated amino 
acid species. The coupling times and methods were as follows: Ala, symmetrical 
anhydride (SA), 1 hour 20 minutes; Phe, SA, 1 hour 10 mins & HOBt activated ester 
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(AE), 45 mins; lie, SA, 35 mins & AE, over night; Leu, SA, 8 equivalents, 3 hours. 
(Yield peptide-resin 540mg). 
Cleavage was carried out by stirring the peptide-resin in 90% TFA!H20 (5m1) under 
nitrogen for 1.5 hours. The crude peptide (42mg) was shown by analytical HPLC to 
contain few impurities. Since the purpose of the synthesis was to check the utility of 
the resin, not to obtain a molecule for biological testing, the peptide was not purified. 
FAB MS: MH 534 (for C26H44N705 expect 534.7); 
HPLC: (column D; gradient I; loop 2m1) R 11.7 mm. 
KU14b ICE pro region 1-119 
The synthesis was carried out on a 0.1 mmole scale, starting with FmocAsp(O'Bu)-
resin (0.16mmol/g, 635mg). The Asn and Gin residues were protected by Mbh 
groups, and the Cys residues by MeOPhenac. Standard double couple cycles for 
large peptides were used throughout, except in four regions, '2L-'5R, 44K-49T, 58621
and 711..761  where extended coupling times were used. Approximately one third of 
the peptide-resin (627mg dry weight) was removed from the reaction vessel after 
coupling of 63P. The final Fmoc was left on the resin (yield Fmoc-peptide-resin 
1.31g). From the deprotection profile, and an Fmoc loading test of the completed 
peptide, it was estimated that the overall coupling efficiency was approximately 40%. 
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The final Fmoc was removed by sonicating the peptide-resin in 20% piperidine! 
DMF for 15 minutes, followed by filtration and washing with DMF, dioxan, DMF, 
and drying with ether. TbFmoc was loaded using standard methodology (see section 
3.2.6). 
Deprotection and cleavage from the resin (118mg) was carried out using the TMSBr 
cleavage procedure (see section 3.2.8) for 6 hours. Lyophilisation gave crude 
TbFmoc-peptide as a fluffy, white solid (60mg). Crude TbFmoc-peptide (18mg) was 
dissolved in 70% acetonitrile/water (7m1) and stirred with porous graphitised carbon 
(PGC) (3 50mg) for 15 minutes. The suspension was filtered through a layer of celite 
in a 1cm diameter, straight-sided sinter funnel. The PGC column was washed with 
70% acetonitrile/water (15m1) and 50% iso-propanol/6M guanidine HC1 (15m1), both 
washing solutions being passed through the column twice. The TbFmoc group was 
cleaved from the peptide, and the peptide washed from the column, by passing a 10% 
solution of piperidine in 50% iso-propanol/6M guanidine HC1 (20m1) through the 
column twice. 
The deprotection filtrate was neutralised by the addition of acetic acid (2m1) and the 
iso-propanol removed in vacuo. The peptide solution was desalted by gel filtration 
through a 10mm x 75cm G50 Sephadex gel column, eluted with 30% acetic 
acid/water, running at 20mllhour, 30 minute fractions being collected. The relevant 
fractions (5, 6 & 7) were combined and lyophilised to give cysteine-protected peptide 
(5mg). 
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Removal of the cysteine protecting groups was carried out using mercuric acetate. 
Peptide (16.3mg, approx. 1.1 9x 1 0 3mmol) was dissolved/suspended in 50% acetic 
acid/water (lOml), and mercuric acetate (6mg, 1.43xlO 2mmol, 16 equivalents) was 
added. The reaction mixture was stirred overnight, after which -mercaptoethano1 
(BME) (0.5m1) was added and the mixture stirred overnight once more. The Hg"- 
BME complex, which formed a fine suspension, was removed by centrifugation and 
the supernatant was subjected to gel filtration as before (yield 5mg). A quantitative 
Ellman's test gave an average of 1.8 free thiols per molecule. 
AAA: Asp13 11.37, Thr7 6.53, Ser8 5.57, Glu17  18.30, Pr03 1.66, Gly8 7.66, Ala9 8.90, 
Cys3 2.48, Val7 7.47, Met5 6.15, 11e7 7.53, Leu13 12.22, Tyr3 1.18, Phe2 1.91, Lys9 
8.07, Ar95 4.28. 
KU17 HIV,,,B gp120 Lys 364-378 ProD.VaI 445-459 
Lys Ser Ser Gly Gly Asp Pro Glu lie Val Thr His Ser Phe Asn Cys Pro D.Vai 
Cys Ser Ser Asn lie Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly 
The synthesis was carried out on a 0.25 mmole scale using Fmoc-Gly-resin 
(0.615mmol/g, 406mg). Double couple cycles were used throughout, 10Val-21Ser 
being given extended coupling times. Cys was protected with StBu  groups. Asn was 
coupled without side-chain protection. The efficiency of the final coupling was 65% 
(yield Fmoc-peptide-resin 1.348g). 
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Fmoc-peptide-resin (370mg) was sonicated with 20% piperidine/DMF for 10 
minutes, filtered and washed successively with DMF, dioxan and ether. The peptide 
was deprotected and cleaved from the resin by stirring with TFA (9m1), water (lml) 
and anisole (0.5m1) under nitrogen for 3 hours. The crude peptide (249mg) was 
purified by preparative HPLC (column J; 5m1/min; gradient (t, %B) 
(0,30)(1 8,45)(20,90)(22,30)) to give the cysteine-protected peptide (45mg) 
TOF MS: MH 3538.8 (for C149H246N41050S4 expect 3540.1); 
HPLC: (column D; gradient I; loop 2ml) Rt 16.7 mm; 
To remove the S'Bu protecting groups, peptide (55mg) was dissolved in 5%H20/TFE 
(20m1) and tributylphosphine (50p1) was added. The mixture was stirred for 2 hours 
40 minutes. Most of the solvent was removed in vacuo and the peptide was 
precipitated by the addition of ether. The peptide was filtered and washed with 
further ether, before being dissolved in aqueous acetic acid for lyophilisation (yield 
53.5mg). 
Air oxidation of the peptide was carried out by vigorous stirring in 50mM 
ammonium acetate buffer (pH 8, 500m1) for 7 days. Lyophilisation and preparative 
HPLC (column H; 5m1/min; gradient (t,%B) (0,10)(17,32)(19,90)(21,10)) gave the 
oxidised title compound (yield 8.5mg). 
TOF MS: MH 3359.5 (for C141H228N41050S2 expect 3361.7); 
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HPLC: (column E; gradient I; loop 2m1) Rt 15.4 mm; 
AAA: Asp4 4.07, Thr3 2.85, Ser5 4.37, G1u1 1.20, Pr02 2.16, G1y5 5.11, Cys2 1.74, 
Va12 1.93, lie2 1.63, Leu3 2.93, Phe1 1.15, His1 0.97, Lys1 0.98, Arg1 0.96. 
KU18 HIVIIIB gp120 Lys 364-377 ACPC 446-459 
Lys Ser Ser Gly Gly Asp Pro Glu lie Val Thr His Ser Phe Asn ACPC Ser Ser 
Asn lie Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly 
The synthesis was carried out on a 0.2 mmole scale using Fmoc-Gly-resin (0.615 
mmol/g, 325mg) in two stages. The synthesis proceeded as normal, employing 
standard double couple cycles, until 17  Ser, when it was interrupted. The resin was 
removed from the reaction vessel and added to the HOCt activated ester of 
FmocACPC, preformed by stirring FmocACPC (0.4mmol, 140mg) and HOCt 
(0.4mmol, 63mg) in the presence of DIC (0.4mmol, 64p1) in DMF/dioxan (1:1, 5m1) 
for 10 minutes. The reaction mixture was sonicated over night at 26°C. The resin 
was then filtered and washed, and returned to the reaction vessel for completion of 
the synthesis by standard methodology. The deprotection profile showed a 
significant drop of about 19% in coupling efficiency for the cyclopentyl residue. 
However this was probably, at least partly, due to mechanical losses associated with 
transferring the resin between reaction vessels. The overall coupling efficiency was 
66% (yield peptide-resin 901.5mg). 
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Deprotection and cleavage were carried out by stirring resin (290mg) in TFA (lOmi) 
with water (imi), thioanisole (0.5m1) and anisole (0.5m1) under nitrogen for 3 hours. 
The crude peptide (200mg) was purified by preparative HPLC (column J; 5m1/min; 
gradient (t,%B) (0,10)(40,90)(42,10)) and lyophilised to give the title compound 
(13mg). 
TOF MS: MH 3072.9 (for C131H213N38047 expect 3072.4); 
HPLC: (column E; gradient I; loop 5m1) Rt 16.2mm; 
AAA: Asp4 4.59, Thr3 3.14, Ser5 4.65, G1u1 1.13, Pro1 1.17, G1y5 5.71, Va11 0.96, 
Ile2 1.83, Leu3 3.59, Phe1 1.03, His1 1.01, Lys1 1.01, Arg 1.20; 
CD: 	 a-helix 	 n-sheet 	 random coil 
50mM sodium borate 
buffer 	 0% 	 51% 	 48% 
50% TFE/sodium 
borate buffer 	 11% 	 53% 	 37% 
Fluorescence Assay 
The assay was run at 30°C. The assay buffer (100mM sodium HEPES, pH 7.5, 
10mM DTT, 10% sucrose, 0.1% CHAPS, 3m1) was placed in a cuvette with the 
substrate, AcTyrVa1A1aAspAMC, (10mM in DMF, 15t1), and allowed to equilibrate 
to the assay temperature. A variable volume (15-60[d) of an aqueous solution (10-
20mM) of the test peptide was added to the cuvette, followed by cell lysate 
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containing crude ICE (1 5p1, provided by Dr D Giegel, Parke-Davis Pharmaceuticals, 
Ann Arbor, MI). The cuvette was inverted 3 times to mix the contents and returned 
to the fluorimeter, when recording of the timed spectrum commenced immediately. 
The change in fluorescence of the sample was followed over 15 minutes, a data point 
being recorded every second. The excitation wavelength used was 380nm and the 
emission 460nm; the slit width used for both was 10.0. 
HPLC Assay 
Assay buffer (39i.il), enzyme lysate (10.tl) and test peptide solution (10mM in water, 
1 jil) were mixed in a 0.5ml Eppendorf tube and incubated at 30°C for variable times 
(1-24 hours). The enzyme mixture was injected onto a Vydac C18 analytical column, 
and an increasing acetonitrile gradient run as follows: (t,%B) (0,5)(20,30)(22,5). 
KU16 prolL-1f3 117-122 
Ala Pro Val Arg Ser Leu 
The synthesis was carried out on a 0.24mmole scale, starting with FmocLeu-resin 
(0.62mmol/g, 3 87mg) and using standard double couple cycles throughout. The 
overall coupling efficiency was 93% (yield peptide-resin 533mg). 
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Deprotection and cleavage were carried out by stirring peptide-resin (3 20mg) in TFA 
(lOmi) with water (imi) and anisole (200pJ) under nitrogen for 1.5 hours. 
Lyophilisation gave a white fluffy solid which was shown to be a single product by 
analytical HPLC (yield 65mg). 
FAB MS: MH 643 (for C28H51N908 expect 642.8); 
HPLC: (column D; loop 2ml; gradient (t,%B) (0,5)(20,30)(22,5)) Rt 10.7 mm; 
AAA: Ser1 0.90, Pro1 1.02, Ala1 1.05, Val1 1.03, Leu1 0.99, Arg1 1.02. 
KU15 proIL-1 111-116 
Glu Ala Tyr Val His Asp 
The synthesis was begun on a 0.25mmole scale, starting with FmocAsp(OtBu)-resin 
(0.57mmol/g, 440mg). As approximately half of the resin was removed after the 
coupling of 3Tyr, an accurate estimate of the coupling efficiency could not be made 
from the deprotection profile (yield peptide-resin 286mg). 
Deprotection and cleavage were carried out as for KU16, analytical HPLC again 
showing a single product (yield 92mg). 
FAB MS: MH 734 (for C32H44N8012 expect 733.8); 
HPLC: (conditions as for KU92) R1 8.0 mm; 
AAA: Asp1 0.99, Glu1 1.14; Ala1 1.03, Va11 0.96, Tyr1 0.98, His1 0.91. 
111 
4. References 
CA Dinarello; Adv. Immunol. (1989) 44:153 
JW Larrick; Immunol. Today (1989) I0:61 
K Ye, BD Clark & CA Dinarello; Immunol. (1992) 75427 
SP Eisenberg, MT Brewer, E Verderber, P Heimdal, BJ Brandhuber & RC 
Thompson; Proc. Nat!. Acad. Sci. USA (1991) I:5232 
B Henderson, ER Pettipher & GA Higgs; Brit. Med. Bu!!. (1987) 43415 
AA van de Loo, OJ Arntz & WB Van den Berg; Clin. Exp. Immunol. (1992) 
87:196 
S Ruschen, W Stellberg & H Wamatz; Clin. Exp. Immunol. (1992) 9:32 
iT-I Schwab, SK Anderle, RR Brown, FG Dalldorf & RC Thompson; 
Infec. Immun. (1991)59:4436 
T Akatsu, N Takahashi, N Udagawa, K Imamura, A Yamaguchi, K Sato, N 
Nagata & T Suda; I. Bone. Mm. Res. (1991) :183 
G Murphy & RM Hemby; J Rheumatol. (1992) 19(suppl 32):61 
R Pacifici; Calcif Tiss. mt. (1992) 50:295 
NC Wood,E Dickens, JA Symons & GW Duff; Clin. Immunol. Immunopatho!. 
(1992) 62:295 
CA Dinarello; Curr. Op. Immunol. (1991) :941 
BJ Graves, MH Hatada, WA Hendrickson, JK Miller VS Madison & Y Satow; 
Biochem. (1990) 29:2679 
15: 	B Veerapandian, GL Gilliland, R Raag, AL Svensson, Y Masui, Y Hirai & 
TL Poulos; Proteins: Struct. Funct. Gen. (1992) 12: 10 
B Mosley, DL Urdal, KS Prickett, A Larsen, D Cosman, PJ Conlon, S Gillis & 
SK Dower; J Biol. Chem. (1987) 262:2941 
S Tate, Y Kikumoto, S Ichikawa, M Kaneko, Y Masui, T Kamogashira, 
M Ouchi, S Takahashi & F Inagaki; Biochem. (1992) 31:2435 
DJ Hazuda, JC Lee & PR Young; I Biol. Chem. (1988) 23.:8473 
RC Fuhlbrigge, SM Fine, ER Unanue & DD Chaplin; Proc. Nati. Acad. Sci. 
USA (1988) 5:5649 
A Heguy, CT Baldari, S Censini, P Ohiara & JL Telford; I. Biol. Chem. (1993) 
268:10490 
F Colotta, F Re, M Muzio, R Bertini, N Polentarutti, M Sironi, JG Gin, 
SK Dower, JE Sims & A Mantovani; Science (1993) 21:472 
R Solari, N Smithers, N Kennard, K Ray & S Grenfell; Biochem. Pharmacol. 
(1994) 47:93 
112 
JE Sims, CJ March, D Cosman,MB Widmer, HR MacDonald, CJ McMahan, 
CE Grubin, JM Wignall, JL Jackson, SM Call, D Friend, AR Alpert, S Gillis, 
DL Urdal & SK Dower; Science (1988) 241:585 
J Saklatvala & F Guesdon; J. Rheumatol. (1992) 19(suppl 32):65 
E Labriola-Tompkins, C Chandran, KL Kaffka, D Biondi, BJ Graves, M 
Hatada, VS Madison, J Karas, PL Killian & G Ju; Proc. Nat!. A cad. Sci. USA 
(1991) 88:11182 
GM Clore, PT Wingfield & AM Gronenborn; Biochem. (1991) 3.0:2315 
KM Brown, AV Muchmore & DL Rosenstreich; Proc. Nat!. Acad. Sci. USA 
(1986) 83:9119 
C Hession, JM Decker, AP Sherboim, S Kumar, CC Yue, RJ Mattaliano, 
R Tizard, E Kawashima, U Schmeisser, S Herleky, EP Chow, CA Bume, 
A Shaw & AV Muchmore; Science (1987) 23.7:1479 
JA Symons, JA Eastgate & GW Duff; J. Exp. Med. (1991) 124:1251 
MK Spriggs, DE Hruby, CR Maliszewski, DJ Pickup, JE Sims, RML Buller & 
J VanSlyke; Cell (1992) 71:145 
A Alcami & GL Smith; Cell (1992) 71:153 
CH Hannum, CJ Wilcox, WP Arend, FG Joslin, DJ Dripps, PLHeimdal, 
LG Armes, A Sommer, SP Eisenberg & RC Thompson; Nature (1990) 343.:336 
SP Eisenberg, RJ Evans, WP Arend, E Verderber, MT Brewer, CH Hannum & 
RC Thompson; Nature (1990) 343.:341 
DJ Dripps, BJ Brandhuber, RC Thompson & SP Eisenberg; J. Biol. Chem. 
(1991) 2:10331 
CA Dinarello & RC Thompson; Immunol. Today (1991) 12:404 
BJ Stockman, TA Scahill, M Roy, EL Ulrich, NA Strakalaitis, DP Brunner, 
AW Yem & MR Deibel; Biochem. (1992) 31:5237 
SW Chensue, KS Warrington, AE Berger & DE Tracey; Am. J. Pathol. (1992) 
140:269 
WM Siders, JC Klimovitz & SB Mizel; J. Biol. Chem. (1993) 268:22170 
E Orino, S Sone, A Nii &T Ogura; Jlmmunol. (1992) 142:925 
HL Wong, GL Costa, Mt Lotze & SM Wahl; .1. Exp. Med. (1993) 122:775 
iN Kline, LJ Geist, MM Monick, MF Stinski & GW Hunninghake; J. 
Immunol. (1994) .12:2351 
M Tanihara, Y Suzuki, C Fujiwara, C Abe, E Abe, T Suda & Y Mizushima; 
Biochem. Biophys. Res. Comm. (1992) 1:912 
PR Sleath, RC Hendrickson, SR Kronheim, CJ March & RA Black; J. Biol. 
Chem. (1990) 2:14526 
113 
AD Howard, MJ Kostura, N Thronberry, GJF Ding, G Limjuco, J Weidner, 
JP Salley, KA Hogquist, DD Chaplin, RA Mumford, JA Schmidt & MJ Tocci; 
J. Immunol. (1991)147:2964 
D MacLean; PhD Thesis, University of Edinburgh (1991) 
NA Thornberry, HG Bull, JR Calaycay, KT Chapman, AD Howard, 
MJ Kostura, DK Miller, SM Molineaux, JR Weidner, J Aunins, KO Elliston, 
JM Ayala, FJ Casano, J Chin, GJF Ding, LA Egger, EP Gaffney, G Limjuco, 
OC Palyha, SM Raju, AM Rolando, JP Salley, T-T Yamin, TD Lee, JE 
Shively, M MacCoss, RA Mumford, JA Schmidt & MJ Tocci; Nature (1992) 
356:768  
DP Cerretti, CJ Koziosky, B Mosley, N Nelson, K VaniNess, TA Greenstreet, 
CJ March, SR Kronheim, T Druck, LA Cannizzaro, K Huebner & RA Black; 
Science (1992) 5:97 
KP Wilson, iF Black, JA Thompson, EE Kim, JP Griffith, MA Navia, 
MA Murcko, SP Chambers, RA Aldape, SA Raybuck & DJ Livingston; Nature 
(1994) .2:270 
RA Black, SR Kronheim & PR Sleath; FEBS Lett. (1989) 242:386 
MJ Kostura, MJ Tocci, G Limjuco, J Chin, P Cameron, AG Hillman, 
NA Chartrain & JA Schmidt; Proc. Natl. Acad. Sci. USA (1989) 86:5227 
MA Nett, DP Cerretti, DR Berson, J Seavitt, DJ Galbert, NA Jenkins, 
NG Copeland, RA Black & DD Chaplin; J. Immunol. (1992) 149:3254 
J Yuan, S Shaham, S Ledoux, HM Ellis & HR Horvitz; Cell (1993) 25641 
M Miura, H Zhu, R Rotello, EA Hartweig & J Yuan; Cell (1993) 2.5:653 
KT Chapman; Bioorg. Med. Chem. Lett. (1992) 2:613 
AMM Mjalli, KT Chapman, M MacCoss & NA Thornberry; Bioorg. Med. 
Chem. Lett. (1993) 3:2689 
RA Black, PR Sleath & SR Kronheim; International Patent Number: 
WO 91/15577; 17 October 1991 
NA Thornberry, EP Peterson, JJ Zhao, AD Howard, PR Griffin & KT 
Chapman; Biochem. (1994) 3.3:3934 
DJ Pickup, BS Ink, W Hu, CA Ray & WK Joklik; Proc. Natl. Acad. Sci. USA 
(1986) 	:7698 
CA Ray, RA Black, SR Kronheim, TA Greenstreet, PR Sleath, GS Salvensen 
& 	DJ Pickup; Cell (1992) 9:597 
RB Merrifield; I Am. Chem. Soc. (1963) 85:2149 
RB Merrifield; J. Am. Chem. Soc. (1964) :304 
FC McKay & NF Albertson; I. Am. Chem. Soc. (1957) 29:4686 
114 
S Sakakibara, M Shin, M Fujino, Y Shimonishi, S Inoue & N Inukai; Bull. 
Chem. Soc. Jpn. (1965) 3.:1522 
WL Haas, EV Krumkalns & K Gerzon; J Am. Chem. Soc. (1966) :1988 
P Sieber & B Iselin; Helv. Chim. Acta. (1968) 51:614 
C Bin, W Lochinger, G Stahnke & P Lang; Justus Liebigs Ann. Chem. (1972) 
2:162 
GR Matsueda & JM Stewart in Peptides: Chemistry, Structure, Biology (1975) 
pp333-339 (ed. R Walter & J Meienhofer) Ann Arbor Sci. Publ., Ann Arbor, 
MI 
LA Carpino & GY Han; J Org. Chem. (1972) 31:3404 
KM Otteson, RL Noble, PD Hoeprich, KT Shaw & R Ramage; Applied 
Biosystems Res. News (June 1993) 
E Atherton, DL Clive & RC Sheppard; J. Am. Chem. Soc. (1975) 91:6584 
RB Merrifield & V Littau in Peptides 1968 pp1  79-182 (ed. E Bricas) North 
Holland Publ., Amsterdam 
SS Wang; J. Am. Chem. Soc. (1973) 25:1328 
BF Gisin & RB Merrifield; .1. Am. Chem. Soc. (1972) 94:3102 
K Poduska & H Gross; Chem. Ber. (1961) 94:527 
E Atherton, M Caviezel, H Over & RC Sheppard; .JC.S. Chem. Comm. (1977) 
p819 
M Bodanszky; Nature (1955) .1.25:685 
J Pless & RA Boissonnas; He/v. Chim. Acta. (1963) 4:1609 
L Kisfaludy, JE Roberts, RH Johnson, GL Mayers & L Kovacs; J. Org. Chem. 
(1970) 3.5:3563 
GHL Nefkens & GI Tesser; J. Am. Chem. Soc. (1961) 3:1263 
GW Anderson, JE Zimmerman & FM Callahan; J. Am. Chem. Soc. (1964) 
86:1839 
W Konig & R Geiger; Chem. Ber. (1970) 103.:788 
LA Carpino; J. Am Chem. Soc. (1993) 1.15:4397 
A Davison; PhD Thesis (Edinburgh) (1993) 
DK Miller, JR Calaycay, KT Chapman, AD Howard, MJ Kostura, 
SM Molineaux & NA Thornberry; Ann. NYAcad. Sci. (1993) 25:133 
NPC Walker, RV Talanian, KD Brady, LC Dang, NJ Bump, CR Ferenz, 
S Franklin, T Ghayur, MC Hackett, LD Hammill, L Herzog, M Hugunin, 
W Houy, JA Mankovich, L McGuiness, E Orlewicz, M Paskind, CA Pratt, 
P Reis, A Summani, M Terranova, JP Welch, L Xiong, A Moller, DE Tracey, 
R Kamen & WW Wong; Cell (1994) 78:343 
T Komiyama, CA Ray, DJ Pickup, AD Howard, NA Thornberry, EP Peterson 
& G Salvensen; I Biol. Chem. (1994) 29:19331 
GD Rose, LM Gierasch & JA Smith; Adv. Protein Res. (1985) 31:1 
A Otaka, T Koide, A Shide & N Fujii; Tet. Lett. (1991) 32:1223 
C Garcia-Echeverria, F Albericio, M Pons, G Barany & E Giralt; Tet. Lett. 
(1989) 3.0:2441 
R Eritja, JP Ziehier-Martin, PA Walker, TD Lee, K Legesse, F Albericio & 
BE Kaplan; Tetrahedron (1987) 4.3.:2675 
R Jaenicke & R Rudolph in Protein Structure: a practical approach (1990) 
p211 (ed. TE Creighton), OUP. 
PKC Paul, PA Burney, MM Campbell & DJ Osgusthorpe; Bioorg. Med. Chem. 
Lett. (1992) 2:141 
JB Ball & PF Alewood; J. Mol. Recognit. (1990) 355 
N Brakch, M Rholam, H Bonsetta & P Cohen; Biochem. (1993)32:4925 
AJ Schulze, R Huber, W Bode & RA Engh; FEBS Lett. (1994) 344:117 
Z Szewczuk, BF Gibbs, SY Yue, EO Purisima & Y Konishi; Biochem. (1992) 
31:9132 
AM Kelly; PhD Thesis, University of Edinburgh (1994) 
D Baker, JL Silen & DA Agard; Proteins: Struct. Funct. Gen. (1992)L2:339 
S Irving; PhD Thesis, University of Edinburgh (1993) 
M Royo, J Alsina, E Giralt, U Slomczynska & F Albericio; Proc. 13 
1h  Amer. 
Pept. Symp. (1993) 116 
AR Brown, PhD Thesis, University of Edinburgh (1995) 
R Ramage & G Raphy; Tet. Lett. (1993) 3Th385 
AR Brown, SL Irving & R Ramage; Tet. Lett. (1993) 34:3129 
TD Pallin; PhD Thesis, University of Edinburgh, 1993. 
U Olshevshky, E Helseth, C Furman, J Li, W Haseltine & J Sodroski; I. Virol. 
(1990) 4:5701 
GJ Cotton; PhD Thesis, University of Edinburgh (1994) 
A Kelly; personal communication 
G Cotton; personal communication 
116 
Courses & Conferences Attended 
Organic Research Seminars, various speakers, 1991-94 
Royal Society of Chemistry Perkin Division Scottish Meeting, various speakers, 
Heriot-Watt 1991, Edinburgh 1992, Aberdeen 1993. 
The Royal Society of Edinburgh Symposium on Protein Engineering, various 
speakers, Edinburgh, 1992 
Medicinal Chemistry, Professor R Baker, Merck Sharp & Dohme, 1992-93 
Chemical Development in the Pharmaceutical Industry, various speakers, SmithKline 
Beecham, 1993-94 
NMR spectroscopy, Dr IH Sadler, Edinburgh University, 1993 
Innovation & Perspectives in Solid Phase Synthesis, various speakers, Oxford, 31 
Aug -4 Sept 1993 
New Horizons in Anti-Inflammatory Therapy, various speakers, London, 11 May 
